

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

State	Bill	Status	Category	Summary	Sponsor
AZ	SB 1387	Referred to Senate Rules Committee	Cost Review (Rate Setting)	<p>This measure establishes the Prescription Drug Affordability Board, which will access pricing information for prescription drugs by entering into a memorandum of understanding with another state to which manufacturers already report pricing information. The board will identify: (1) brand drugs that have either a launch wholesale acquisition cost (WAC) of \$30,000 or more or a WAC increase of \$3,000 or more in a year; (2) biosimilars that have a launch WAC that is not at least 15% lower than the referenced brand biologic; and (3) generics that have a WAC of \$100 or more or that increased by 200% or more during the past 12 months. The board will determine whether to conduct an affordability review for each identified product. If the board finds that the cost of a drug has led or will lead to an affordability challenge, the board must establish an upper-payment limit that will apply to all purchases and payer reimbursements.</p> <p>This measure also establishes the prescription drug affordability fund consisting of assessments on all manufacturers. The board will annually assess each manufacturer on the manufacturer's relative share of gross revenues from drug sales in the state.</p>	Sen. Juan Mendez (D)
AZ	SB 1549	Introduced	Transparency	<p>This measure requires the Department of Health Services to compile a list of essential diabetes drugs and the wholesale acquisition cost (WAC) of each drug on the list. The department must also compile a separate list that details which essential diabetes drugs have been subject to an increase in WAC by a percentage that is equal to or greater than the percentage increase in the consumer price index in the preceding year or twice the percentage increase in the consumer price index during the preceding two years.</p> <p>Any manufacturers with drugs on these lists must submit a report to the department that contains pricing information. Manufacturers with drugs on the second list will be required to submit a justification for their price increases.</p> <p>This measure also requires pharmacy benefit managers to submit rebate information for drugs included on the manufacturer lists.</p>	Sen. Rebecca Rios (D)
AZ	SB 1600	Introduced	Importation	This measure requires the Department of Health Services to design a wholesale importation program that complies with federal law.	Sen. Rebecca Rios (D)
CA	ACR 105	Adopted in Assembly; referred to Senate Health Committee	Volume Purchasing	This is a resolution that encourages the governor to engage with Washington and Oregon and others who wish to partner with California to lower prescription drug prices across the country.	Asm. David Chiu (D)
CA	SB 852	Referred to Senate Rules Committee	Other	This measure states the intent of the legislature to introduce legislation to require the state of California to manufacture generic prescription drugs for the purposes of controlling prescription drug costs.	Sen. Richard Pan (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

CO	HB 1160	Referred to House Health and Insurance Committee	Transparency	<p>under their health insurance plans, including information about rebates received from prescription drug manufacturers, a certification regarding how rebates were accounted for in insurance premiums, and a list of all pharmacy benefit managers (PBMs) with whom they contract. Insurers will report the top 50 drugs for which they paid, the 50 costliest drugs, the 50 drugs that had the highest increase in total annual plan spending, the 50 drugs that caused the greatest increase in premiums, the top 50 most frequently prescribed drugs, and the 50 drugs for which the insurer received the largest rebates.</p> <p>This measure requires prescription drug manufacturers to notify the commissioner, state purchasers, health insurers, PBMs, pharmacies, and hospitals when the manufacturer increases the price of certain drugs more than specified amounts or introduces a new specialty drug in the commercial market. Manufacturers must report drugs with a price of more than \$50 if the increase is 10% or more in a year, 16% or more over two years, or 20% or more over three years. For drugs that meet these thresholds, manufacturers will be required to submit pricing information.</p> <p>This measure requires PBMs to annually report specified information to the commissioner regarding rebates and administrative fees received from manufacturers.</p> <p>This measure also requires certain nonprofit organizations to compile and submit to the commissioner an annual report indicating the amount of each payment, donation, subsidy, or thing of value received by the organization from a drug manufacturer, health insurer, or PBM.</p>	Rep. Dominique Jackson (D)
CO	HB 1078	Passed House	Pharmacy Benefit Manager	<p>This measure prohibits a pharmacy benefit manager (PBM) from reimbursing a pharmacy in an amount less than the amount that the PBM reimburses any affiliate for the same pharmacy services. The bill also prohibits PBMs from retroactively reducing payment on a clean claim submitted by a pharmacy unless the PBM determine the claim was not a clean claim.</p>	Rep. Sonya Jacquez-Lewis (D)
CO	HB 1198	Referred to House Health and Insurance Committee	Pharmacy Benefit Manager	<p>This measure prohibits health insurers and pharmacy benefit managers (PBMs) from using misleading advertisements, charging a pharmacy a fee for adjudicating a claim, reimbursing an independent pharmacy less than an affiliate, and modifying their drug formulary at any time during the benefit year.</p> <p>This measure also requires insurers and PBMs to submit their programs for compensating pharmacies and their formularies to the Insurance Commissioner. This bill requires PBMs to report to the commissioner the amount the PBM expects to receive from the carrier for pharmacist services that are eligible for reimbursement under the health benefit plan. The commissioner can review this information to ensure reimbursement is fair and reasonable.</p> <p>Under the bill, a carrier or PBM must submit an annual report with information detailing the amount they actually paid to the pharmacy, the amount the PBM receive from the carrier for pharmacist services, and the amount of rebates the carrier or PBM received.</p> <p>This measure requires carriers that use PBMs to ensure that their PBMs comply with the requirements in the bill.</p>	Rep. Lois Landgraf (R)
CO	SB 107	Referred to Senate Health and Human Services Committee	Transparency	<p>This measure directs the Department of Health Care Policy and Financing, or a third party contracted with the department, to collect, analyze, and report prescription drug production cost data regarding the 20 highest-cost prescription drugs per course of therapy and the 20 highest-cost prescription drugs by volume that were purchased or paid for by the departments of corrections, human services, personnel, and health care policy and financing during the 2019-2020 fiscal years. Upon receipt of a list of the highest-cost prescription drugs, the department must request from the manufacturers of the drugs on the list information showing the basis for and components of the wholesale acquisition cost (WAC) of each drug on the list. The department must analyze the data received from manufacturers and report its findings, specifying the percentage of the WAC that is attributable to each component driving the WAC. The department will be required to provide an annual transparency report.</p>	Sen. Joann Ginal (D)
CO	SB 119	Referred to Senate Health and Human Services Committee	Importation	<p>This measure expands the wholesale Canadian prescription drug importation program to include prescription drug suppliers from nations other than Canada upon the enactment of legislation by the US Congress authorizing such practice.</p>	Sen. Joann Ginal (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

CT	HB 5018	Referred to Joint Insurance and Real Estate Committee	Importation	This measure requires the Commissioner of Consumer Protection to establish a program that will be known as the "Canadian legend drug importation program." The program will provide for the importation of safe and effective legend drugs from Canada that have the highest potential for cost savings in the state.	Rep. Joe Aresimowicz (D)
DE	HCR 61	Passed House	Volume Purchasing	This measure extends the date by which the final report of the Interagency Pharmaceuticals Purchasing Study Group is due to the legislature to Jan. 31, 2020.	Rep. Raymond Seigfried (D)
DE	HCR 66	Passed House/Passed Senate	Pharmacy Benefit Manager	This measure extends the due date of the Pharmacy Reimbursement Trask Force report to March 31, 2020.	Rep. Adria Bennett (D)
DE	HB 216	Passed House Economic Development/Banking/Insurance and Commerce Committee	Pharmacy Benefit Manager	This measure authorizes a pharmacist or pharmacy to decline to dispense a prescription drug or provide pharmacy service to an "insured" if the amount reimbursed is less than the pharmacy acquisition cost. This bill also prohibits a pharmacy benefit manager (PBM) from reimbursing a pharmacist or pharmacy for a drug in an amount less than the PBM reimburses itself or an affiliate for the same drug.	Rep. Adria Bennett (D)
DE	HB 287	Referred to House Health and Human Development Committee	Volume Purchasing	This measure implements recommendations of the Interagency Pharmaceuticals Purchasing Study Group. The bill establishes the Interagency Pharmaceutical Purchasing Collaborative. The bill requires the collaborative to conduct a data analysis of current pharmaceutical purchasing prices paid by state agencies to create a data analytic profile. The collaborative must also build a market database by assessing the value, as determined by cost and patient outcome, of individual drugs and calculating the volume of individual drug purchases. The collaborative will then use that database to identify opportunities to leverage the total volume of pharmaceutical purchases to negotiate lower prices. This could include a group purchasing group or a consortium with other states. This bill additionally requires state agency contracts with pharmaceutical manufacturers to include specific transparency provisions.	Rep. Raymond Seigfried (D)
FL	HB 1293/1724	Referred to House Health Market Reform Subcommittee/Referred to Senate Banking and Insurance Committee	Cost Review (Rate Setting)	This measure establishes a Prescription Drug Affordability Commission to review prescription drug costs. Drug manufacturers must report to the commission if they increase the wholesale acquisition cost (WAC) of a brand-name drug by more than 10% of \$3,000 in a year or if they introduce a brand-name drug to market that has a WAC of \$30,000 per year or more. Manufacturers must report if they plan to introduce a biosimilar with a WAC that is not at least 15% lower than the cost of the referenced brand-name product. They must also report if they increase the WAC of a generic by more than 25% or \$300 in a year or introduce a generic that has a WAC of \$1,200 or more. All of these reports must be made at least 30 days before the planned increase or introduction takes place and must include a justification for the price. The commission will review all drugs reported. If the commission finds that the cost of a drug under review creates excess cost for payers and consumers, the commission will establish the rate that must be billed to, and paid by, payers, pharmacies, providers, wholesale distributors and consumers. An advisory council will help the commission make determinations.	Rep. Margaret Good (D), Sen. Janet Cruz (D)
FL	HB 961/SB 1444	Referred to House Appropriations Health Market Reform Subcommittee; referred to Senate Banking and Insurance Committee	Pharmacy Benefit Manager	This measure provides that pharmacy benefit managers (PBMs) have a fiduciary duty to enrollees and payers and must work in the best interests of enrollees and payers. This measure also contains a provision that specifies what information must be made available on a maximum allowable cost list and how often the list must be updated. This measure also prohibits PBMs from spread pricing and reimbursing a pharmacy an amount for a drug that is less than the amount the PBM reimburses an affiliate or less than the actual cost incurred by the pharmacy for providing the drug. This measure also prohibits PBMs from retroactively denying or reducing reimbursement.	Rep. Jackie Toledo (R), Sen. Gayle Harrell (R)
FL	HB 7045	Passed House Appropriations Committee; referred to House Health and Human Services Committee	Pharmacy Benefit Manager	Under this bill, a contract between a health insurer and a pharmacy benefit manager (PBM) must require the PBM to submit an annual report to the insurer detailing rebate information, including the aggregate amount of rebates the PBM received and the aggregate amount of such rebates the PBM received that were not passed through to the insurer, the aggregate amount of administrative fees paid to the PBM by the insurer, and the aggregate amount of revenue generated by the PBM through the use of spread pricing.	Health Market Reform Subcommittee

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

FL	HB 109/SB 116	Referred to House Health Market Reform Subcommittee/Substituted; passed Senate Banking and Insurance Committee; referred to Agriculture, Environment, and General Government Subcommittee	Coupons/Cost Sharing	This measure requires insurers to cap the total amount of cost sharing that an enrollee is required to pay for a covered insulin drug at \$100 per 30-day supply, regardless of the amount of type of insulin needed.	Rep. Nicholas Duran (D),
FL	SB 696/HB 561	Banking and Insurance Committee/Referred to House Health and Human Services Health Market Reform Subcommittee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to submit an annual report detailing the aggregated dollar amount of rebates from drug manufacturers and the aggregate amount of rebates passed to health insurers and the insured at the point of sale. This measure also requires insurers to apply third-party payments, discounts, or financial assistance made on behalf of an insured individual toward the insured's deductible, copay, cost-sharing responsibility, or out-of-pocket maximums.	Sen. Debbie Mayfield (R), Rep. Thad Altman (R)
FL	SB 1338	Substituted, passed Senate Banking and Insurance Committee; referred to Appropriations Subcommittee on Health and Human Services	Pharmacy Benefit Manager	This measure authorizes the Office of Insurance Regulation to examine pharmacy benefit managers (PBMs) and requires annual reports from PBMs about rebates. Under this measure, the insurance office may require a health insurer to submit to the office for review any contract for the administration of pharmacy benefits. The office can require a health insurer to cancel the contract if the fee paid by the insurer are unreasonably high compared to other contracts. This measure includes a provision that requires PBMs and pharmacies to agree that if the PBM is provided a rebate or other discount, that the PBM must pass through those discounts to the health insurer.	Sen. Tom Wright (R)
FL	SB 1682	Referred to Senate Banking and Insurance Committee	Transparency	<p>This measure prohibits pharmacy benefit managers (PBMs) from conducting or participating in spread pricing or from sharing cost information with an enrollee. It also prohibits a PBM from reimbursing a pharmacy or pharmacist an amount which is less than the amount the PBM reimburses an affiliate, less than the actual cost incurred by the pharmacy, or different from the combined maximum allowable cost and dispensing fees for a drug. This bill prohibits PBMs from retroactively denying a claim or from making a referral.</p> <p>Under this bill, PBMs must submit quarterly reports to payer clients that detail any income resulting from pricing discounts, rebates of any kind, inflationary payments, etc. The PBM must ensure that such income and financial benefits are passed through in full, at least quarterly, to the payer to reduce the cost of prescription drugs and pharmacy services for enrollees. PBMs will also be required to submit rebate information to Florida's Department of Business and Professional Regulation.</p> <p>This measure also requires manufacturers to annually disclose pricing information to the department. Manufacturers must report when the price of a drug with a wholesale acquisition cost of at least \$100 increases by 40% or more during the preceding three years or by 15% in the preceding calendar year.</p> <p>Insurers are also required to submit an annual report to the Insurance Commissioner detailing the names of the 25 most frequently prescribed drugs, the percentage of any increase in annual net spending for drugs, the percentage of any increase in premiums attributable to drugs, the percentage of specialty drugs with utilization management requirement prescribed, and any premium reductions that were attributable to the utilization management.</p> <p>This measure additionally requires a health insurer or PBM to base an enrollee's cost-sharing for a prescription drug on the net price of the drug, rather than the list price.</p>	Sen. Jose Rodriguez (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

FL	SB 1836	Referred to Senate Governmental Oversight and Accountability Committee	Pharmacy Benefit Manager	This measure prohibits pharmacy benefit managers (PBMs) from imposing on a covered individual a copayment that exceeds the claim cost of a prescription drug. This measure also stipulates that if a participant in the state group health insurance plan uses a pharmacy discount program or manufacturer rebate, and such use results in a lower cost than would have been paid for a covered prescription drug had the participant use the state group health insurance plan, the state plan must apply the payment made by the participant toward the participant's deductible and out-of-pocket maximums.	Sen. Aaron Bean (R)
GA	SB 313	Referred to Senate Insurance and Labor Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to use the national average drug acquisition cost as a benchmark for the ingredient drug product component of a pharmacy's reimbursement for drugs. PBMs are prohibited under this bill for paying or reimbursing a pharmacy in an amount less than the national average drug acquisition cost or an amount less than the current select specialty pharmacy rate. PBMs cannot reimburse a pharmacy less than they would reimburse an affiliate. Additionally, PBMs cannot engage in any practice that includes imposing a point-of sale fee or retroactive fees. This measure also prohibits PBMs from patient steering. This measure requires PBMs to pass on to the health plan 100% of all rebates and other payments it receives from pharmaceutical manufacturers. Under this bill, PBMs are required to charge a health plan the same price for a prescription drug as it pays a pharmacy. PBMs must apply any third-party payment or other out-of-pocket expenses made on behalf of an insured toward an insured's cost share or copay responsibility. Additionally, PBMs owe a fiduciary duty to a health plan and an insured under this measure.	Sen. Dean Burke (R)
HI	HB 267/SB 1328	Conference committee appointed	Transparency	This measure requires drug manufacturers that produce a drug with a wholesale acquisition cost (WAC) of more than \$40 to notify each benefit plan and pharmacy benefit manager of any planned price increase that will result in a 16% or more increase in the WAC over a two-year period. Notice of planned increases must be provided at least 60 days before the increase.	Rep. Roy Takumi (D), Sen. Rosalyn Baker (D)
HI	HB 1442/SB 1521	Referred to House Finance Committee	Pharmacy Benefit Managers	This measure establishes requirements for pharmacy benefit managers (PBMs) and maximum allowable cost. This bill requires PBMs to disclose where an equivalent drug can be obtained at or below the maximum allowable cost.	Rep. Della Belatti (D), Sen. Rosalyn Baker (D)
HI	HB 1608	Amended; passed House Consumer Protection and Commerce Committee; referred to House Finance Committee	Importation	This measure requires the Department of Health to administer a wholesale prescription drug importation program that uses Canadian suppliers.	Rep. Roy Takumi (D)
HI	HB 1609	Amended; passed House Consumer Protection and Commerce Committee	Pharmacy Benefit Manager	This measure establishes that a pharmacy benefit manager (PBM) has a fiduciary duty to its clients. This measure also limits the amount an enrollee will pay at the point of sale to the applicable copayment, the allowable claim amount, the amount the enrollee would pay without insurance or the amount the pharmacy will be reimbursed for the drug. Under this bill, PBMs will be required to submit annual transparency reports containing rebate information. Finally, this measure requires PBMs to obtain a license, rather than just register, before they can do business in the state.	Rep. Roy Takumi (D)
HI	HB 1796	Referred to House Finance Committee	Study	This measure establishes the insulin drug task force within the Department of Commerce and Consumer Affairs to study whether cost-sharing limits should be placed on prescription insulin drugs.	Rep. John Mizuno (D)
HI	HB 1805/ SB 2276	Referred to House Consumer Protection Committee/Amended; passed Senate Commerce, Consumer Protection and Health Committee	Transparency	This measure requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers (PBMs) if a proposed price increase of a drug with a wholesale acquisition cost (WAC) of at least \$50 would result in a 16% or more increase over a two-year period. Notice must be given at least 60 days prior to the increase. This measure also requires the insurance commissioner to identify annually up to 10 drugs on which the state spends significant health care money and for which the WAC increased by a total of 50% or more during the prior two years or by 20% in the preceding year. Manufacturers of drugs on the list will be required to submit pricing information to the commissioner.	Rep. Roy Takumi (D), Sen. Rosalyn Baker (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

HI	HB 2712/SB 3095	Amended; passed House Health Committee; referred to House Consumer Protection Committee/Referred to Senate Consumer Protection and Health Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) from reimbursing a 340B-covered entity differently than any other pharmacy that contracts with a PBM based on the covered entity's participation in the 340B program. This measure prohibits a PBM from reimbursing a 340B-covered entity or contract pharmacy for a drug on a maximum allowable cost basis, conducting spread pricing, and from retroactively denying or reducing a claim for reimbursement. This measure also requires PBMs to report to the insurance commissioner on a quarterly basis information regarding rebates.	Rep. Stacelynn Eli (D), Sen. Maile Shimabukuro (D)
HI	SB 507	Referred to Senate Commerce, Consumer Protection and Health Committee	Pharmacy Benefit Managers	This measure requires pharmacy benefit managers (PBM) to notify contracting pharmacies of changes to maximum allowable costs (MAC) for any drug 15 days before the change. This measure also requires PBMs to disclose where an equivalent drug can be obtained at or below the maximum allowable cost when a MAC appeal is upheld on appeal. This measure also allows a pharmacy to decline to dispense a drug if the reimbursement is less than the acquisition cost	Sen. Donna Kim (D)
HI	SB 1401/HB 1361	Conference committee appointed	Pharmacy Benefit Managers	This measure requires pharmacy benefit managers (PBM) to obtain a license and prohibits a PBM from providing financial incentives to covered persons as incentives to use a retail pharmacies. This measure also requires PBMs to submit annually a transparency report regarding rebates received from manufacturers.	Sen. Rosalyn Baker (D), Rep. Roy Takumi (D)
HI	SB 2009	Amended; passed Commerce, Consumer Protection, and Health Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured individual is required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed.	Sen. Karl Rhoads (D)
HI	SB 2276	Amended; passed Senate Commerce, Consumer Protection and Health Committee	Pharmacy Benefit Manager	This measure establishes business practice and transparency reporting requirements for pharmacy benefit managers (PBMs). Under this bill, PBMs will have a fiduciary duty to a covered entity client. This measure prohibits a PBM from requiring an enrollee from making a payment at the point of sale for a drug in an amount greater than the lesser of the applicable copayment, the allowable claim amount, the amount the person would pay without insurance, or the amount the pharmacy will be reimbursed for the drug from the PBM. This measure additionally requires all PBMs to submit a transparency report to the Insurance Commissioner that must include rebate information. This bill also requires PBMs to obtain a license to operate in the state.	Sen. Rosalyn Baker (D)
HI	SB 2280	Amended; passed Senate Commerce, Consumer Protection and Health Committee	Pharmacy Benefit Manager	This measure prohibits pharmacy benefit managers (PBMs) from engaging in self-serving business practices. This measure also replaces the existing PBM registration requirements with a licensure requirement. This bill increases PBM reporting requirements to the insurance commissioner.	Sen. Rosalyn Baker (D)
HI	SB 2443	Referred to Senate Commerce, Consumer Protection, and Health Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured individual is required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed. This measure also requires the Insurance Commission, with the assistance of the attorney general, to investigate prescription insulin drug pricing and submit a report to the legislature, governor and general public.	Sen. Russell Ruderman (D)
HI	SB 2444	Referred to Senate Commerce, Consumer Protection and Health Committee	Importation	This measure requires the Department of Health to administer a wholesale prescription drug importation program that uses Canadian suppliers.	Sen. Russell Ruderman (D)
HI	SB 3045/HB 2561	Referred to Consumer Protection and Health Committee/Amended; passed House Health Committee; referred to House Consumer Protection Committee	Study	This measure requires the Insurance Commissioner to study the feasibility of establishing a mechanism to review prescription drug costs and set levels of reimbursements and rates without additional cost to the state.	Sen. Rosalyn Baker (D), Rep. Roy Takumi (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

ID	H 363	Referred to House Health and Welfare Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to register with the Department of Insurance. This bill also requires PBMs to review and update maximum allow cost price information at least once every seven business days and to establish a process by which a network pharmacy may appeal the reimbursement for a generic drug. This measure prohibits a PBM from retroactively denying a claim.	Health and Welfare Committee
ID	H 386	Referred to Senate Commerce and Human Resources Committee	Pharmacy Benefit Manager	This measure prohibits pharmacy benefit managers (PBMs) from prohibiting pharmacists from sharing cost information with patients. This measure also establishes the criteria for including a drug on a PBM's maximum allowable cost (MAC) list and requires the PBMs review and update their MAC lists at least once every seven business days. This measure also prohibits a PBM from retroactively denying a claim.	House Health and Welfare Committee
IL	HB 53	Referred to House Prescription Drug Affordability and Accessibility Committee	Transparency	This measure requires manufacturers of brand name or generic prescription drugs to notify state purchasers, health insurers, pharmacy benefit managers and the general assembly about specified increases in drug prices at least 60 days before an increase, and the cost of new prescription drugs within three days of US Food and Drug Administration approval. Notice must be provided if the brand manufacturer is increasing the wholesale price of the brand name drug by more than 10% or \$10,000 during a 12-month period or if the generic manufacturer is increasing the wholesale price by 25% during a 12-month period. Price increases must be justified by manufacturers.	Rep. Mary Flowers (D)
IL	HB 156	Referred to Senate Assignments Committee	Transparency	This measure requires health insurers to disclose certain rate and spending information concerning prescription drug pricing information to the Department of Public Health, which in turn must create a list annually of the state's high-spend drugs. This measure also requires drug manufacturers to notify the attorney general when they plan to introduce a new drug at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. This measure also requires a health insurer to apply the same cost-sharing requirements to interchangeable biological products as apply to generic drugs under the policy. Additionally, this measure instructs pharmacists to select the lowest-priced interchangeable biological product in place of a biologic drug, rather than allowing a pharmacist to substitute only if certain requirements are met. Finally, this bill requires that when a pharmacist receives a prescription from a Medicaid enrollee, the pharmacist must select the preferred drug or biologic from the state's preferred drug list.	Rep. Mary Flowers (D)
IL	HB 204	Referred to House Appropriations - Human Services Subcommittee on Medicaid and Managed Care	Other	This measure reinstates the pharmaceutical assistance program for seniors that was eliminated by Public Act 97-689. The program will execute contracts with pharmacies to dispense covered prescription drugs and establish maximum limits on the size of prescriptions.	Rep. Steve Davisson (R)
IL	HB 891	Referred to House Rules Committee	Pharmacy Benefit Managers	This measure allows a pharmacy or pharmacist to provide an insured consumer with information about the amount of the insured's cost-share for a prescription drug. Under this bill, neither a pharmacy nor a pharmacist will be penalized by a pharmacy benefit manager (PBM) for discussing cost information with a consumer or for selling a lower-priced drug if one is available.	Rep. Joe Sosnowski (R)
IL	HB 1441	Referred to House Rules Committee	Importation	This measure establishes a wholesale Canadian drug importation program that allows the state to be a licensed wholesaler of imported drugs.	Rep. Anna Moeller (D)
IL	HB 2174	Referred to Senate Insurance Committee	Other	This bill requires that every health insurance carrier that provides coverage for prescription drugs shall ensure that no fewer than 25% of certain individual and group plans offered shall apply a pre-deductible, flat-dollar copayment structure to the entire drug benefit.	Rep. Kathleen Willis (D)
IL	HB 2880	Referred to House Rules Committee	Other	This measure imposes a tax on each establishment that makes the first sale of a covered outpatient drug within the state. Under this bill, "first sale" means an initial sale of a covered outpatient drug from a manufacturer to a wholesaler or from a wholesaler to a pharmacy. This bill provides that the tax shall be charged against and paid by the establishment making the first sale and shall not be added as a separate charge or line item or otherwise passed down on any invoice to the customer.	Rep. Will Guzzardi (R)
IL	HB 3187	Referred to House Rules Committee	Pharmacy Benefit Manager	This measure provides that upon request by a party contracting with a pharmacy benefit manager (PBM), a PBM must disclose the actual amounts paid by the PBM to the pharmacy. Under this bill, a PBM will provide notice to the party contracting with the PBM about any consideration that the PBM receives from the manufacturer for dispense as written prescriptions once a generic or biologically similar product becomes available.	Rep. Deanna Mazzochi (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

IL	HB 3493	Referred to Prescription Drug Affordability and Accessibility Committee	Cost Review (Rate Setting)	This measure creates the Prescription Drug Affordability Board. The board must identify brand drugs and biologics that have a launch wholesale acquisition cost (WAC) of \$30,000 or more or an increase of \$3,000 in a year. The board must also identify biosimilar drugs that have a launch WAC that is not at least 15% lower than the reference biologic, as well as generic drug with a WAC of \$100 or more, or that increased by 200% or more in a year. For drugs identified, the board will conduct a cost review. If the board determines the cost of a drug will lead to an affordability challenge for the state or patients, the board can establish an upper payment limit that applies to all purchases and payer reimbursements.	Rep. Will Guzzardi (D)
IL	HB 4362	Referred to House Rules Committee	Importation	This measure establishes a wholesale Canadian drug importation program that allows the state to be a licensed wholesaler of imported drugs.	Rep. Anna Moeller (D)
IL	SB 667	Signed by Governor (Public Act 101-0625)	Coupons/Cost Sharing	This measure requires the attorney general to investigate the pricing of prescription insulin drugs to ensure adequate consumer protections for consumers and to determine whether additional consumer protections are necessary. This measure also provides that insurers must limit the total amount an enrollee is required to pay for insulin to \$100 per 30-day supply, regardless of the type and amount needed. On January 1 of each year, the limit on the amount that an enrollee is required to pay will increase by a percentage equal to the change from the preceding year of the Consumer Price Index.	Sen. Andy Manar (D)
IL	SB 3058	Referred to Senate Assignments Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers to register with the Insurance Department.	Sen. Andy Manar (D)
IL	SB 3059	Referred to Senate Assignments Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers to register with the Insurance Department.	Sen. Andy Manar (D)
IL	SB 3117	Referred to Senate Insurance Committee	Pharmacy Benefit Manager	This measure provides that a pharmacy benefit manager (PBM) has a fiduciary duty to a third party with which the PBM has entered into a contract to manage the pharmacy benefit plan of the third party. This bill requires PBMs to notify the third party in writing of an activity, policy, or practice that presents a conflict of interest that interferes with the ability of the PBM to discharge its fiduciary duty.	Sen. Andy Manar (D)
IL	SB 3159	Referred to Senate Assignments Committee	Pharmacy Benefit Manager	This measure requires a pharmacist to disclose to the consumer at the point of sale the current pharmacy retail price for each prescription medication the consumer intends to purchase. If the consumer's cost-sharing amount exceeds the current pharmacy retail price, the pharmacist must disclose to the consumer that the pharmacy retail price is less than the cost-sharing amount.	Sen. Andy Manar (D)
IN	HB 1005	Amended on House floor	Importation	This measure establishes the Importation of Prescription Drugs Program for the importation of prescription drugs. The program will be administered by the Department of Health.	Rep. Donna Schaibley (R)
IN	HB 1042	Passed House	Pharmacy Benefit Manager	This measure requires a pharmacy benefit manager (PBM) to obtain a license from the Department of Insurance. PBMs are prohibited from including mail order pharmacies in the determination of network adequacy under this bill. This bill authorizes the Insurance Commissioner to adopt rules to specify licensure, financial standards and reporting requirements that apply to PBMs. Any violations of PBM regulations will be considered unfair and deceptive acts under this bill.	Rep. Steven Davisson (R)
IN	HB 1116	Referred to House Insurance Committee	Transparency	<p>This measure requires drug manufacturers to notify the Department of Insurance if the increase of a wholesale acquisition cost (WAC) of a brand drug exceeds more than 20 percent during a 12-month period or if the WAC of a generic drug with a cost of at least \$10 increases by 20% during any 12-month period. Notice is required 60 days before any increase takes effect. Manufacturers must also notify the department 60 days prior to the introduction of a new drug that has a WAC of at least \$670.</p> <p>This measure also requires pharmacy benefit managers (PBMs) and wholesalers to submit an annual report to the Insurance Department with all the data elements specified in NASHP's Model Act report template within 60 days of receiving notification by the department indicating the specific drug groups for which reporting is required.</p> <p>Under this measure, insurers must report spending on prescription drugs for each of the top 25 prescription drugs and drug groups in the following categories: 1) the greatest total spending; 2) the greatest total spending per user of any drug in the drug group; 3) the highest year-over-year increase in total spending; and 4) the highest year-over-year increase in total spending per user of any drug in the drug group. For each drug, the insurer must report all data elements specified in the NASHP Model Act template.</p> <p>This bill requires each reporting entity to pay an annual assessment to support the operational costs of the activities of the department.</p>	Rep. Robin Shackelford (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

IN	HB 1207	Referred to Senate Health and Provider Services Committee	Pharmacy Benefit Manager	This measure provides that a health plan or pharmacy benefit manager (PBM) may not require a pharmacy or pharmacist to collect a higher copayment for a prescription drug from an enrollee than the health plan provider allows the pharmacy or pharmacist to retain.	Rep. Steve Davisson (R)
IN	HB 1219	Referred to House Insurance Committee	Coupons/Cost Sharing	This measure requires health plans to include any amounts paid by a covered individual or on behalf of a covered individual when calculating the covered individual's cost sharing requirement. Under this measure, the cost sharing requirement for a prescription drug under a state employee health plan, a policy of accident and sickness insurance, or a health maintenance organization (HMO) will be calculated at the point of sale and based on a price that is reduced by an amount equal to at least 75% of all rebates received by the insurer in connection with dispensing the drug. This bill also prohibits insurers or HMOs from requiring an insured to pay a cost sharing requirement of more than \$250 for a 30-day supply of an individual prescription drug.	Rep. Danny Bentley (R)
IN	SB 38	Referred to Senate Health and Provider Services Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers to annually report rebate information to the insurance commissioner.	Sen. Ed Charbonneau (R)
IN	SB 160	Introduced; referred to Senate Health and Provider Services Committee	Other	<p>This measure requires insurers to only offer health plans that do not require a covered individual to pay a deductible for covered prescription drugs and that provide that the cost-sharing requirement for a covered individual for any given prescription drug cannot exceed the cost-sharing amounts detailed in the plan's summary of benefits.</p> <p>Under this bill, a covered individual's cost-sharing requirement for a prescription drug is calculated at the point of sale and must be based on a price that is reduced by an amount equal to at least 85% of all rebates received or estimated to be received by the insurer in connection with the dispensing or administration of the drug.</p> <p>When calculating a covered individual's contribution to any applicable cost-sharing requirement, an insurer must include any amount paid by another person on behalf of the individual.</p>	Sen. Mike Bohacek (R)
IN	SB 241	Referred to House Insurance Committee	Pharmacy Benefit Manager	<p>This measure requires a pharmacy benefit manager (PBM) to obtain a license from the Department of Insurance. PBMs are prohibited from including mail order pharmacies in the determination of network adequacy under this bill. This bill authorizes the Insurance Commissioner to adopt rules to specify licensure, financial standards, and maximum allowable cost list compliance that apply to PBMs. This measure requires PBMs to submit an annual report that contains rebate information. The Insurance Commissioner will publish the report on the department's website.</p> <p>This measure also lays out how PBMs can set maximum allowable cost (MAC) pricing and the process by which a contracted pharmacy or pharmacy services administrative organization can appeal MAC pricing set by a PBM.</p>	Sen. Liz Brown (R)
IN	SB 337	Referred to Senate Insurance and Financial Institutions Committee	Pharmacy Benefit Manager	This measure requires the registration of pharmacy benefit managers (PBMs) and allows for audits by clients of PBMs. Under this bill, a PBM must provide notice to a party contracting with the PBM regarding any consideration that the PBM receives from a pharmacy manufacturer for any name brand dispensing of a prescription when a generic or biologically similar product is available for the prescription.	Sen. Victoria Spartz (R)
IN	SB 421	Referred to Senate Insurance and Financial Institutions Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured individual is required to pay for a prescription drug at \$50 per 30-day supply, regardless of the amount or type of insulin needed. This measure also requires insurers to provide coverage without cost sharing for auto-injectable epinephrine that is prescribed to individual younger than 18 years old.	Sen. Eddie Melton (D)
IA	HF 2138/HSB 501/SF 2113	Introduced/Passed House Subcommittee/Referred to Senate Subcommittee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured is required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed.	House Committee on Human Resources, Sen. Carrie Koelker (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

IA	HF 2253	Referred to House Commerce Committee	Transparency	<p>This measure requires drug manufacturers to file an annual report with the commissioner of insurance that discloses the wholesale acquisition cost (WAC) for all prescription drugs manufactured for sale in the state. If a prescription drug sold in the state has a cost of \$100 or more for a 30-day supply and the cost increases 40% or more over three consecutive calendar years, or increases 15% or more during a single calendar year, the manufacturer of the prescription drug must file a report with the commissioner within 30 days of the increase.</p> <p>This bill additionally requires each health carrier to submit an annual report to the commissioner that contains information regarding the names of the 25 prescription drugs most frequently covered by the carrier, as well as the percent increase in annual spending by the carrier attributable to prescription drug spending.</p>	Rep. Shannon Lundgren (R)
KS	HB 2478	Referred to House Insurance Committee	Pharmacy Benefit Manager	This measure replaces the pharmacy benefit manager registration requirement with a licensure requirement.	House Insurance Committee
KS	HB 2598	Referred to House Insurance Committee	Pharmacy Benefit Manager	This bill requires pharmacy benefit managers (PBMs) to obtain a license from the Department of Insurance. This measure requires that all compensation remitted by, or on behalf of, a pharmaceutical manufacturer to a carrier or to a PBM be remitted directly to the covered person at the point of sale or remitted to and retained by the plan sponsor to lower premiums. This measure also requires PBMs to prepare a quarterly transparency report summarizing data relating to prescription benefits. This measure also prohibits discrimination of 340B-covered entities and the retroactive reduction or denial of a claim. Under this bill, a PBM cannot pay or reimburse a pharmacy in an amount less than the pharmacy's usual and customary price, the national average drug acquisition cost or the pharmacy's wholesale acquisition cost. This bill details maximum allowable cost requirements.	House Insurance Committee
KS	HB 2631	Introduced	Pharmacy Benefit Manager	This measure prohibits pharmacy benefit managers (PBM) from disparately treating any pharmacy by imposing terms on such pharmacy that differ from those imposed or required of other pharmacies based solely on such pharmacy's designation as a 340B-covered entity. "Disparate terms" include the exclusion of 340B entities from provider networks, reimbursing 340B-covered entities less than a PBM affiliate, and assessing any fee upon a 340B entity on the basis that the 340B entity participates in the 340B drug pricing program. This measure also prohibits a PBM from collecting from an enrollee any cost-share amount for a drug at the point of sale that exceeds the lesser of the copayment, the amount the enrollee would pay without insurance or the contracted amount for the drug.	House Health and Human Services Committee
KY	HB 12/SB 118	Referred to House Health and Family Services Committee/Referred to Senate Banking and Insurance Committee	Coupons/Cost Sharing	This measure caps the cost-sharing price or copay of insulin at \$100 for a 30-day supply.	Rep. Danny Bentley (R)/Sen. Reginald Thomas (D)
KY	HB 72	Referred to House Banking and Insurance Committee	Coupons/Cost Sharing	This measure requires an insurer to apply financial assistance received by an insurers from an enrollee toward that enrollee's cost-sharing requirements.	Rep. Danny Bentley (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

KY	HB 398	Referred to House Banking and Insurance Committee	Pharmacy Benefit Manager	<p>Under this bill, an insurers, pharmacy benefit managers (PBM) or any other administrator of pharmacy benefits cannot require an enrollee to pay a cost-sharing amount for pharmacy services that is greater than what was paid by or charged to the patient for the services at the point of sale, use a mail order pharmaceutical distributor, or pay cost sharing for services received from a nonaffiliated pharmacy that is greater than what would other be imposed if the enrollee used a pharmacy affiliate or a mail-order pharmaceutical distributor. This bill also contains network adequacy requirements for PBMs.</p> <p>This measure prohibits insurers and PBMs from reducing payment for pharmacy services under a reconciliation process to an effective rate or reimbursement, including the use of generic effective rates, dispensing effective rates, brand effective rates, and direct and indirect remuneration fees, and any other mechanism that reduces or aggregately reduces payment for pharmacy services. It also prohibits insurers and PBMs from retroactively reducing or denying a claim or assessing any fees against the pharmacy that are related to a claim for services. This measure additionally prohibits insurers and PBMs from reimbursing a pharmacy less than the amount the insurers or PBM reimburses a pharmacy affiliate. It prohibits PBMs and insurers from reimbursing for the ingredient drug product component of a pharmacy services that is less than the national average drug acquisition cost.</p> <p>Under this bill, a PBM owes a fiduciary duty to the insurer. This bill requires PBMs to monitor the activities carried out in the state on behalf of the insurer. This bill prohibits PBMs from engaging in spread pricing. This measure requires PBMs to submit quarterly reports to the Insurance Commissioner detailing rebate information.</p> <p>This measure establishes the Pharmacy Benefits Management Advisory Council, which is charged with making recommendations to the commissioner as to the implementation, interpretation, and enforcement of insurance laws relating to PBMs.</p>	Rep. Steve Sheldon (R)
KY	HB 400	Referred to House Banking and Insurance Committee	Pharmacy Benefit Manager	This measure requires a pharmacy benefit manager (PBM) to file a disclosure that lists pharmacy affiliates. This bill prohibits a PBM from sharing pharmacy records with a pharmacy affiliate and referring a patient to a pharmacy affiliate.	Rep. Steve Sheldon (R)
KY	SJR 5	Referred to Senate Health and Welfare Committee	Study	This resolution directs the Cabinet for Health and Family Services to create a task force to study prescription drug transparency and affordability.	Sen. Tom Buford (R)
KY	SB 23	Referred to Senate Health and Welfare Committee	Other	<p>This measure requires the Board of Pharmacy to implement an insulin assistance program by Jan. 1, 2021. Under the program, the board must reimburse participating pharmacies for insulin products and supplies that are dispensed by the pharmacy to qualified individuals and seek participation in the program by pharmacies in all areas of the state. Pharmacy participation in the program is voluntary. Participating pharmacies will dispense insulin and related supplies to qualified individuals at no cost.</p> <p>The board must develop and make available a financial need form that ensures those who receive insulin do not have the financial means to pay for insulin and that they do not receive health coverage through the state medical assistance program. Qualified individuals are eligible for 90 days and can extend or renew their eligibility for an additional 90. There is no limit on the number of times an individual can extend their eligibility.</p> <p>Under this measure, a manufacturer that delivers or distributes any qualified insulin product must pay an insulin product fee. The fee is \$1.50 per unit.</p> <p>Beginning Dec. 1, 2020, a manufacturer or wholesale distributor must provide the board with information about each insulin product it sells in the state, including the wholesale acquisition cost for the product. They must also report every sale, delivery, or other distribution within or into the state of any insulin product made to any practitioner, pharmacy or hospital. The board will then use this data to identify qualified insulin products and prepare invoices for each manufacturer and wholesale distributor that is required to pay an insulin product fee. Manufacturers and wholesale distributors will be required to remit payment to the board. Wholesale distributor and manufacturer licenses will be renewed contingent upon payment of the insulin product fee. All fees collected will be deposited into the insulin assistance fund.</p>	Sen. Phillip Wheeler (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

KY	SB 50	Passed Senate Health and Welfare Committee; referred to Senate Rules Committee	Pharmacy Benefit Manager	This measure requires the Department for Medicaid Services to establish and directly administer an outpatient pharmacy benefit program for all Medicaid beneficiaries. This bill allows the department to contract with a third-party administrator (TPA) on a fee-for-service basis for the purpose of administering the outpatient pharmacy benefit program for all Medicaid recipients. If the department contracts with a TPA, that TPA must utilize the formulary, reimbursement methodologies, and dispensing fee established by the department.	Sen. George Wise (R)
KY	SB 69	Referred to Senate Banking and Insurance Committee	Coupons/Cost Sharing	This measure caps the cost-sharing price or copay of insulin at \$100 for a 30-day supply. State employee health plans are required to comply with this bill.	Sen. Phillip Wheeler (R)
ME	LD 1387	Carry over to next session	Importation	This measure allows an individual to import a prescription drug from a pharmacy in Canada that is allowed to export drugs under Canadian regulations for personal use. This measure prohibits the personal importation of controlled substances.	Rep. Troy Jackson (D)
ME	LD 1591	Carry over to next session	Importation	This measure instructs the Department of Health and Human Services to design a wholesale prescription drug importation program.	Rep. Michael Brennan (D)
ME	LD 1928	Referred to Health Coverage, Insurance and Financial Services Committee	Pharmacy Benefit Manager	This bill prohibits a health insurance carrier from retroactively reducing payment on a properly submitted claim by a pharmacy provider. The bill also prohibits a carrier from charging a pharmacy provider or holding a pharmacy provider responsible for any fee related to a claim that is not apparent at the time the carrier processes the claim, or that is not reported on the remittance advice or after the initial claim is adjudicated by the carrier.	Sen. Nate Libby (D)
ME	LD 2095	Referred to Health Coverage, Insurance and Financial Services Committee	Coupons/Cost Sharing	This measure requires health plans to include on their formulary at least one generic drug or biosimilar that has a wholesale acquisition cost (WAC) that is lower than the wholesale acquisition cost for the generic drug or biosimilar's branded pharmaceutical reference product. This bill prohibits any limitation on coverage of or enrollee access to a generic drug or biosimilar that: (1) is more restrictive than any limitation applicable to the branded pharmaceutical reference product for that generic drug or biosimilar if that branded pharmaceutical reference product is included on the formulary; (2) has the effect of favoring the branded pharmaceutical product; or (3) restricts the pharmacies through which enrollees may obtain the generic drug or biosimilar that is not also applicable to the branded pharmaceutical reference product. For each generic drug and biosimilar, the carrier offering the health plan shall provide coverage on a generic cost-sharing tier.	Sen. Troy Jackson (D)
ME	LD 2096	Referred to Health Coverage, Insurance and Financial Services Committee	Coupons/Cost Sharing	This bill provides that a health insurance carrier that provides coverage for prescription insulin drugs may not impose a cost-sharing requirement on the enrollee that results in out-of-pocket costs to the enrollee in excess of \$100 per 30-day supply of insulin.	Rep. Sara Gideon (D)
MD	HB 134	Referred to House Health Insurance Committee	Coupons/Cost Sharing	This measure limits the cumulative amount a covered enrollee is required to pay in copayments or coinsurance for a covered prescription insulin drug to not more than \$100, regardless of the amount or type of insulin needed to fill the prescriptions.	Del. Kirill Reznik (D)
MD	HB 756	Introduced	Pharmacy Benefit Manager	This measure requires the Maryland Medical Assistance Program to establish reimbursement levels, rather than maximum reimbursement levels, for generic drug products. This measure also requires that minimum reimbursement levels be at least equal to the national average drug acquisition cost of the generic product plus the fee-for-service professional dispensing fee. Pharmacy benefit managers that contract with a pharmacy on behalf of a managed care organization will be required to follow these reimbursement guidelines.	Del. Nic Kipke (R)
MD	HB 785	Referred to House Health and Government Operations Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) from requiring that a beneficiary use a mail order pharmacy to fill or refill a prescription as a condition for reimbursing the cost of the drug. This measure also prohibits carriers from prohibiting an enrollee from selecting a pharmacy of the enrollee's choice for pharmacy services, if the pharmacy participates as a contract provider in the health benefit offered by the carrier.	Del. Matt Morgan (R)
MD	HB 885	Referred to House Health and Government Operations Committee	Pharmacy Benefit Manager	This measure stipulates that pharmacy benefit managers (PBMs) have a duty and obligation to the beneficiary and the purchaser to perform all PBM services with care, skill, prudence, diligence, and professionalism and primarily in the best interests of the beneficiary and the purchaser.	Del. Sheree Sample-Hughes (D)
MD	HB 905	Referred to House Health and Government Operations Committee	Other	This measure requires that at the point of prescribing or dispensing a prescription drug to a patient, a prescriber or dispenser must have access to and use technology that provides patient-specific prescription drug benefit and cost information through a real-time transaction. Information displayed through the technology must include all options available to the patient for covering the cost of a drug, including cost coverage options available at the patient's pharmacy of choice, through mail service pharmacies and through specialty pharmacies, as well as cash options.	Del. Emily Shetty (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

MD	HB 943/SB 871	Referred to House Health and Government Operations Committee/Referred to Senate Finance Committee	Pharmacy Benefit Manager	This measure requires a pharmacy benefit manager (PBM) to allow an enrollee to obtain a specialty drug from a dispensing physician. This bill prohibits a PBM from imposing a copayment, coinsurance requirement, or deductible on a beneficiary who uses the services of a dispensing physician who mails or delivers a specialty drug to the beneficiary that is not imposed when the beneficiary uses the services of a mail order pharmacy.	Del. Karen Young (D), Sen. J.B. Jennings (R)
MD	HB 1150	Referred to House Health and Government Operations Committee	Pharmacy Benefit Manager	This measure requires that at least six months before the expiration of a contract for pharmacy benefit manager (PBM) services for the state health and welfare benefits program, the Department of Budget and Management must select a PBM by conducting a reverse auction.	Del. Shane Pendergrass (D)
MD	HB 1307	Referred to House Health and Government Operations Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to maintain adequate pharmacy networks. A mail-order pharmacy cannot be included in a determination of a PBM's network adequacy. Under this bill, if the amount reimbursed by a PBM or a purchaser for a prescription drug is less than the pharmacy acquisition cost for the same prescription drug, the pharmacy may decline to dispense the drug to a beneficiary.	Del. Nic Kipke (R)
MD	SB 669/HB 1095	Referred to Senate Public Health Committee/Referred to House Health and Government Operations Committee	Cost Review (Rate Setting)	This measure stipulates that funding for the Prescription Drug Affordability Board will come from an annual assessment on manufacturers, pharmacy benefit managers, carriers and wholesale distributors. The total amount of fees the board may collect in each calendar year cannot exceed \$2 million.	Sen. Bill Ferguson (D), Del. Adrienne Jones (D)
MD	SB 915/HB 978	Referred to Senate Finance Committee/Referred to House Health and Government Operations Committee	Pharmacy Benefit Manager	This measure requires pharmacy services administrative organizations (PSAO) to obtain a license from the Insurance Commissioner. This bill prohibits a PSAO from refusing to pay or reimburse an independent pharmacy or a pharmacy benefit manager for an arbitrary or capricious reason.	Sen. Ben Kramer (D), Del. Ariana Kelly (D)
MA	H 931	Referred to Joint Financial Services Committee	Transparency	This measure requires three representatives from the pharmaceutical industry to attend the Health Policy Commission's annual public hearing based on information submitted to the Center for Health Information and Analysis. They will be required to share information concerning factors underlying drug costs and price increases, the impact of manufacturer rebates, and the availability of alternative drugs. This bill also requires pharmaceutical manufacturers to provide early notice to the commission for a pipeline drug, an abbreviated new drug application or a biosimilar biologic license. This bill requires manufacturers to report drug pricing information to the commission.	Rep. Gerald Cassidy (D)
MA	H 1013/S 652	Referred to Joint Financial Services Committee/Referred to Joint Financial Services Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) from prohibiting a pharmacy from disclosing to an individual the cost of the prescription medication and the availability of any equivalent medication or alternative methods of purchasing the drug, including cash price. Additionally, under this bill, no PBM can require an individual to make a payment at the point of sale for a covered prescription medication in an amount greater than the amount an individual would pay for the medication without insurance.	Rep. Bradley Jones (R), Sen. Bruce Tarr (R)
MA	H 1055/S 640	Referred to Joint Financial Services Committee/Referred to Joint Financial Services Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) from prohibiting a pharmacy or pharmacist from providing information to a consumer regarding cost sharing or lower-cost alternatives. This measure also contains language regarding maximum allowable cost lists.	Rep. Paul McMurty (D), Sen. Michael Rodrigues (D)
MA	H 1104	Referred to Joint Financial Services Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) from prohibiting a pharmacy or pharmacist from providing information to a consumer regarding cost sharing or lower-cost alternatives. This measure also contains language regarding maximum allowable cost lists.	Rep. Alan Silva (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

MA	H 1133/S 706	Referred to Joint Health Care Financing Committee/Referred to Joint Health Care Financing Committee	Cost Review (Rate Setting)	<p>manufacturers, a drug could lead to an entity increase expenditures above the health care cost growth benchmark or if it would could create challenges to the affordability of health care in the state. A brand name drug or biologic can be reviewed if the product has a launch cost of \$30,000 or more or a wholesale acquisition cost (WAC) of \$3,000 or more. A biosimilar can be reviewed if the launch WAC is not at least 15% lower than the referenced brand biologic. Generic drugs can be reviewed if there is a price increase that results in an increase in the WAC that is equal to 200% or more over a year and the WAC is at least \$100. The review will determine if the commission will set an upper payment limit on the drug. This measure also requires manufacturers to give 60 days' notice prior to a WAC increase of 10% or more for a drug that costs over \$40.</p> <p>This measure also requires a study of the impact of pharmaceutical manufacturing company pricing factors and methodologies and the pharmacy benefit manager (PBM) business model. The top 20 selling drugs in the state will be studied. The Center for Health Information and Analysis will also require PBMs to submit information regarding rebates.</p> <p>This measure also requires the Secretary of Health and Human Services to set a pharmaceutical spending target pursuant to supplemental rebate cost containment. Under this bill, the secretary may directly negotiate supplemental rebate agreements with manufacturers. If a manufacturer and the secretary cannot establish a supplemental rebate agreement, the secretary can require the manufacturer to disclose records relating to the pricing of the drug under consideration. If the secretary deems the manufacturer's price excessive, the secretary can impose a penalty on the manufacturer.</p> <p>This measure requires PBMs to obtain a license and establishes a fiduciary duty to health benefit plans.</p>	Rep. Christine Barber (D), Sen. Jason Lewis (D)
MA	H 1154	Referred to Joint Health Care Financing Committee	Transparency	<p>This measure requires the Center for Health Information and Analysis to annually prepare a list of at least 10 outpatient drugs that the center determines account for a significant share of state health care spending. The manufacturer of a drug on the list must provide an explanation of the increase and aggregate, company-level research and development costs.</p> <p>This measure also requires pharmacies to post notices informing consumers that they can request the current pharmacy retail price for prescription drugs at the point of sale. If the consumer's cost-sharing amount for the drug exceeds the retail price, the pharmacist will charge the consumer the applicable cost-sharing amount or the current retail price. Additionally, this bill prohibits a pharmacy benefit manager (PBM) from preventing pharmacists from disclosing cost information to a consumer.</p>	Rep. Carmine Gentile (D)
MA	H 1162/S 552	Referred to Joint Health Care Financing Committee/Referred to Joint Financial Services Committee	Transparency	<p>This measure requires the Health Policy Commission to annually identify up to 15 prescription drugs on which the state spends significant health care dollars and for which the wholesale acquisition cost has increased by 50% or more over the past five years or by 15% or more over the past 12 months. For each drug on the list, the Attorney General will require manufacturers to submit pricing information.</p> <p>This measure also requires manufacturers to submit a report to the Health Policy Commission for each price increase of a prescription drug that will result in an increase in the average manufacturer price of that drug that is at least 10% over a year. Each year, the commission will hold public hearings based on the reports submitted by manufacturers.</p>	Rep. Kate Hogan (D), Sen. Nick Collins (D)
MA	H 1167	Referred to Joint Health Care Financing Committee	Transparency	<p>This measure requires the Health Policy Commission and the Center for Health Information and Analysis to create annually a list of 10 drugs on which the MassHealth program spends significant health care dollars and for which the WAC has increased by 50% or more over the past five years or by 15% during the previous year. This bill also requires carriers to create annually a list of 10 prescription drugs on which its plans spend significant amounts of their premium dollars, and for which the cost to the plans, net of rebates, has increased by 50 % or more over the past five years or 15% during the previous year.</p> <p>Using both sets of information, the Attorney General will create a list of up to 15 drugs on which the greatest amount of money was spent. Manufacturers of those drugs must submit pricing information to justify the increase in the net cost of the drug..</p>	Rep. Bradley Jones (R)
MA	H 1178	Referred to Joint Health Care Financing Committee	Transparency	<p>This measure requires the Center for Health Information and Analysis to annually prepare a list of at least 10 outpatient drugs that the center determines account for a significant share of state health care spending. The manufacturer of a drug on the list must provide an explanation of the increase and aggregate, company-level research and development costs.</p> <p>This measure also requires pharmacies to post notices informing consumers that they can request the current pharmacy retail price for prescription drugs at the point of sale. If the consumer's cost-sharing amount for the drug exceeds the retail price, the pharmacist will charge the consumer the applicable cost-sharing amount or the current retail price. Additionally, this bill prohibits a pharmacy benefit manager (PBM) from preventing pharmacists from disclosing cost information to a consumer.</p>	Rep. Ronald Mariano (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

MA	H 1193	Referred to Joint Health Care Financing Committee	Cost Review (Rate Setting)	This measure creates the Drug Cost Review Commission. The commission will be notified by a manufacturer of a patent-protected, brand-name drug or biologic if the wholesale acquisition cost (WAC) increases by more than 10% or by \$10,000 during any 12-month period or if the manufacturer intends to introduce to market a brand-name drug that has a WAC of \$30,000 or more. A manufacturer of a generic or off-patent, sole-source brand product must notify the commission if the manufacturer is increasing the WAC by more than 25% or more \$300 during a year. The commission will use a variety of economic factor to determine whether a drug has an excessive cost. If the commission determines a drug has an excessive cost, it will establish the level of reimbursement that will be paid among payers and pharmacies and wholesalers/distributors.	Rep. Lindsay Sabadosa (D)
MA	H 1972	Referred to Joint Public Health Committee	Importation	This measure establishes a wholesale prescription drug importation program.	Rep. Lenny Mira (R)
MA	HB 4134	Governor's Health Care Bill	Cost Review (Rate Setting)	This measure subjects manufacturers of drugs that cost more than \$50,000 per year to the Health Policy Commission accountability process. This measure also imposes a penalty on manufacturers that increase the price of a drug by more than 2% above the rate of inflation in a given year. This bill requires representatives from the pharmaceutical industry to participate in cost trend hearings and requires pharmacy benefit managers to obtain certification from the Department of Insurance.	Governor Charlie Baker (R)
MA	S 601	Referred to Joint Financial Services Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) from charging a health carrier or health benefit plan more than what was paid to the pharmacy for those services. This measure also requires PBMs to submit aggregate rebate information to the Division of Insurance.	Sen. Patricia Jehlen (D)
MA	S 646	Referred to Joint Financial Services Committee	Pharmacy Benefit Manager	This measure requires the Insurance Commissioner to promulgate regulations for the licensing of pharmacy benefit managers.	Sen. Bruce Tarr (R)
MA	S 653	Referred to Joint Financial Services Committee	Transparency	This measure requires insurance issuers that charge enrollees a cost-sharing amount that may result in an excessive consumer cost burden for covered prescription drugs to disclose to enrollees the fact that enrollees may be subject to an excessive cost burden. Under this bill, "excess consumer cost burden" means a cost burden amount charged to an enrollee for a covered drug that is greater than the amount that an enrollee's health insurance issuer pays, or would pay absent enrollee cost sharing.	Sen. Bruce Tarr (R)
MA	S 654	Referred to Joint Financial Services Committee	Pharmacy Benefit Manager	This measure requires the Insurance Commissioner to promulgate regulations for the licensing of pharmacy benefit managers.	Sen. Bruce Tarr (R)
MA	S 659	Became S 2364 (amended out of scope)	Pharmacy Benefit Manager	This measure requires pharmacies to post a notice informing consumers that a consumer may request current pharmacy retail prices at the point of sale. If a consumer's cost-sharing amount exceeds the retail price, the pharmacist must notify the consumer and charge the consumer the applicable cost-sharing amount or the current retail price.	Sen. James Welch (D)
MA	S 695	Referred to Joint Health Care Financing Committee	Volume Purchasing	This measure establishes a special commission to examine the prospect of establishing a system for bulk purchasing and distribution of pharmaceutical products with a significant public health benefit and the potential for significant health care cost savings through overall increased purchase capacity.	Sen. Eric Lesser (D)
MA	S 696/H 3551	Referred to Joint Health Care Financing Committee; Referred to Joint Elder Affairs Committee	Transparency	This measure requires the Health Policy Commission to develop a list of critical prescription drugs for which there is substantial public interest in understanding the development of pricing. The commission will examine multiple cost factors, including the total cost of production per dose, research and development costs and marketing costs. The commission will annually identify the drugs that due to their cost, jeopardize the state's ability to meet the statewide health care cost growth benchmark.	Sen. Eric Lesser (D), Rep. Jose Tosado (D)
MA	S 712	Referred to Joint Health Care Financing Committee	Transparency	This measure requires the Health Policy Commission to conduct an annual study of pharmaceutical manufacturing companies with pipeline drugs, generic drugs, or biosimilar drug products that may have a significant impact on statewide health care expenditures. The Center for Health Information and Analysis will obtain cost information from manufacturer information. This measure also requires pharmaceutical manufacturers to provide early notice to the commission for a pipeline, an abbreviated new drug application for generic drugs, or a biosimilar biologics license application. This measure also requires the attorney general to monitor trends in the health care market and gives the attorney general to investigate manufacturers or pharmacy benefit managers.	Sen. Mark Montigny (D)
MA	S 733	Substituted by S 2397	Pharmacy Benefit Manager	This measure requires a pharmacy to notify consumers that at the point of sale, they may request the current pharmacy retail price. If a pharmacist determines that the cost sharing for a prescription exceeds the current retail price, they shall notify the customer of the pharmacy retail price and the difference between it and the consumer's cost-sharing amount. A pharmacist will charge a customer the applicable cost-sharing or the current pharmacy retail price for that prescription, whichever is less.	Sen. James Welch (D)

<p>MA</p>	<p>S 2397</p>	<p>Substituted for S. 733; passed Senate Ways and Means Committee; amended; substituted by S. 2409</p>	<p>Other</p>	<p>Drugs eligible for review are brand-name drugs or biologics that have a launch WAC of \$50,000 or more for a one-year supply or biosimilar drugs that have a launch WAC that is not at least 15 percent lower than the referenced brand biologic. Public health essential drugs with a WAC of more than \$25,000 for a E45100 one-year supply are also eligible for HPC review. The HPC can require a manufacturer to disclose pricing information in order to review a drug's cost.</p> <p>If, after reviewing a drug, the HPC determines the pricing of the drug does not exceed the proposed value, the HPC must evaluate other ways to mitigate the drug's cost in order to improve access. The HPC can issue recommendations on ways to reduce the cost of the drug, including an alternative payment plan or methodology, a bulk purchasing program, cost-sharing restrictions, and a reinsurance program to subsidize the cost of the drug.</p> <p>If the HPC determines the pricing of a drug exceeds the proposed value, the HPC must request that the manufacturer provide additional information related to the pricing of the drug. The HPC will then determine whether the pricing exceeds the HPC's proposed value. If it does, the HPC will notify the manufacturer and requires the manufacturer enter into access improvement plan. The plan must be generated by the manufacturer, identify the reasons for the drug's price and include specific strategies, adjustments and action steps the manufacturer proposes to address the cost of the drug in order to improve access. The timetable for an access improvement plan cannot exceed 18 months. The HPC will approve any plan that is likely to address the cost so that patient access improves and has a reasonable expectation for successful implementation. After the conclusion of the implementation timetable, a manufacturer must report outcomes to the HPC. If the HPC deems the outcomes insufficient, the HPC will extend the timetable and approve any amendments to the plan.</p> <p>If a manufacturer declines to enter into an improvement plan, the HPC can publicly post the proposed value of the drug, hold a public hearing on the proposed value and solicit public comment. The manufacturer will be required to appear and testify at any hearing held on a drug's proposed value.</p> <p>This measure establishes a four-year program to assess the public health utilization and cost impacts of capping copays and eliminating deductibles and co-insurance requirements for insulin. Under this bill, coverage for insulin cannot be subject to any deductible or coinsurance and copays cannot exceed \$25 per month per insulin prescription.</p> <p>This measure requires PBMs to obtain a license from the Department of Insurance and requires PBMs to report rebate information to the Center for Health Information and Analysis.</p>	<p>Senate Committee on Ways and Means</p>
-----------	---------------	--	--------------	---	---

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

				<p>This measure authorizes the Health Policy Commission (HPC) to review drug costs that could have a significant impact on consumers. Drugs eligible for review are brand-name drugs or biologics that have a launch wholesale acquisition cost (WAC) of \$50,000 or more for a one-year supply or biosimilar drugs that have a launch WAC that is not at least 15% lower than the referenced brand biologic. Public health essential drugs with a WAC of more than \$25,000 for a one-year supply are also eligible for HPC review. The HPC can require a manufacturer to disclose pricing information in order to review a drug's cost.</p> <p>If, after reviewing a drug, the HPC determines the pricing of the drug does not exceed the proposed value, the HPC must evaluate other ways to mitigate the drug's cost in order to improve access. The HPC can issue recommendations on ways to reduce the cost of the drug, including an alternative payment plan or methodology, a bulk purchasing program, cost-sharing restrictions, and a reinsurance program to subsidize the cost of the drug.</p> <p>If the HPC determines the pricing of a drug exceeds the proposed value, the HPC must request that the manufacturer provide additional information related to the pricing of the drug. The HPC will then determine whether the pricing exceeds the HPC's proposed value. If it does, the HPC will notify the manufacturer and requires the manufacturer enter into access improvement plan. The plan must be generated by the manufacturer, identify the reasons for the drug's price and include specific strategies, adjustments and action steps the manufacturer proposes to address the cost of the drug in order to improve access. The timetable for an access improvement plan cannot exceed 18 months. The HPC will approve any plan that is likely to address the cost so that patient access improves and has a reasonable expectation for successful implementation. After the conclusion of the implementation timetable, a manufacturer must report outcomes to the HPC. If the HPC deems the outcomes insufficient, the HPC will extend the timetable and approve any amendments to the plan.</p> <p>If a manufacturer declines to enter into an improvement plan, the HPC can publicly post the proposed value of the drug, hold a public hearing on the proposed value, and solicit public comment. The manufacturer will be required to appear and testify at any hearing held on a drug's proposed value.</p> <p>This measure establishes a four-year program to assess the public health utilization and cost impacts of capping copays and eliminating deductibles and co-insurance requirements for insulin. Under this bill, coverage for insulin cannot be subject to any deductible or coinsurance and copays cannot exceed \$25 per month per insulin prescription.</p> <p>This measure requires pharmacy benefit managers (PBMs) to obtain a license from the Department of Insurance and requires PBMs to report rebate information to the Center for Health Information and Analysis.</p> <p>The measure also creates a special commission to examine the feasibility of establishing a system for the bulk purchasing and distribution of pharmaceutical products with a significant public health benefit and the potential for significant health care cost savings for consumers through overall increased purchase capacity and for making bulk purchasing pricing information available to purchasers in other states.</p>	
MA	S 2409	Substituted for S. 2397; referred to House Committee on Ways and Means	Other		Senate Committee on Ways and Means
MI	HB 4154	Introduced	Transparency	This measure requires a manufacturer to submit an annual report with the Department of Health and Human Services on costs associated with a prescription drug for the preceding calendar year if the drug has a wholesale acquisition cost (WAC) of \$10,000 or more per course of treatment or if the WAC has increased by a total of 25% of more during the last 5 years or by 5% in the last year. Manufacturers will be required to submit pricing information with the report.	Rep. Hank Vaupel (R)
MI	HB 4155	Introduced	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to register with the Department of Insurance. This measure also requires PBMs to submit an annual report with rebate information.	Rep. Hank Vaupel (R)
MI	HB 4235	Referred to Senate Appropriations Committee	Pharmacy Benefit Manager	This is a budget bill. This measure includes a requirement that any contract with a Medicaid managed care organization that relies on a pharmacy benefits manager use a transparent pass-through pricing model, in which the PBM discloses the administrative fee as a percentage of the professional dispensing costs.	Rep. Mary Whiteford (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

MI	HB 4701	Referred to House Insurance Committee	Coupons/Cost Sharing	This measure caps the cost-sharing price or copay of insulin at \$100 for a 30-day supply.	Rep. Sara Cambensy (D)
MI	HB 4702	Referred to House Government Operations Committee	Other	This measure requires the attorney general to investigate pricing of insulin to ensure adequate consumer protections in pricing and whether additional protections are needed. If necessary, the attorney general may issue an administrative subpoena that could require a PBM, carrier or manufacturer to furnish material. By November 1, 2020, the attorney general must submit a report that includes a summary of insulin pricing practices and any public policy recommendations to control and prevent overpricing of insulin.	Rep. John Chirkun (D)
MI	HB 4978	Referred to House Health Policy Committee	Importation	This measure requires the Department of Health and Human Services to establish a wholesale prescription drug importation program from Canada. This measure requires the department to submit a request to the federal government by Jan. 1, 2021.	Rep. Tommy Brann (R)
MI	HB 4979	Referred to House Health Policy Committee	Importation	This measure requires the Department of Health and Human Services to establish an international wholesale prescription drug importation program. This measure requires the department to submit a request to the federal government by Jan. 1, 2021.	Rep. Steven Johnson (R)
MI	HB 5107	Referred to House Health Policy Committee	Importation	This measure requires the Department of Health and Human Services to establish a wholesale prescription drug importation program from Canada. This measure requires the department to submit a request to the federal government by Oct. 1, 2020.	Rep. Darrin Camilleri (D)
MI	HB 5108	Referred to House Health Policy Committee	Transparency	This measure requires manufacturers of drugs that have a wholesale acquisition cost (WAC) that is more than \$40 to notify qualified purchasers if the manufacturer is increasing the WAC by 12% or more during any 24-month period. Notification must be provided at least 60 days before the increase, and the manufacturer must include a justification for the WAC increase. Notification must also include pricing information. Manufacturers must also provide notice if they plan to introduce a drug that exceeds the Medicare specialty drug threshold. This bill also establishes the drug consumer protection commission, which will review manufacturer reports to determine whether a manufacturer's price is excessive or if a price increase is excessive. If the commission determines that a manufacturer has charged an excessive price, the commission will submit a summary of finding to the Attorney General's office with a request that the Attorney General investigate the manufacturer.	Rep. Angela Witwear (D)
MI	HB 5109	Referred to House Health Policy Committee	Price Gouging	This measure prohibits manufacturers from charging excessive prices or unconscionable increases in wholesale acquisition costs (WAC). Under this bill, the Attorney General must investigate any allegation she receives from the drug consumer protection commission.	Rep. Laurie Pohutsky (D)
MI	HB 5457	Referred to House Health Policy Committee	Study	This measure establishes the committee to study drug prices. The committee is tasked with studying issues consumers face related to prescription drug pricing, access and costs, including the process by which a prescription drug moves through the supply chain, the methods health insurers and pharmacy benefit managers use to manage drug costs, the function of manufacturer rebates and discounts, the current trends in prescription drug spending, and the trends in insurance benefit design and the potential impact that changes are having on consumer out-of-pocket prescription drug costs.	Rep. Frank Vaupel (R)
MI	SB 139	PBM provisions vetoed by Governor	Pharmacy Benefit Manager	This measure prohibits the Department of Health and Human Services from entering into contracts with Medicaid managed care organizations that rely on pharmacy benefit managers that do not agree to move to a transparent pass-through pricing model or create new pharmacy administration fees. This measure also contains guidelines detailing which pricing methodologies pharmacies with a certain number of outlets should use.	Sen. Peter MacGregor (R)
MI	SB 525	Referred to Senate Health Policy and Human Services Committee	Importation	This measure allows for the establishment of a wholesale prescription drug importation program from Canada.	Sen Ruth Johnson (R)
MN	HF 704	Referred to House Health and Human Services Policy Committee	Transparency	This measure requires each manufacturer of a prescription drug that has a wholesale acquisition cost (WAC) of \$10,000 or more annually or per course of treatment to file a report with the Commissioner of Health. The report must include information about the total cost for production of the drug, total research and development costs, total costs for clinical trials, and total costs for marketing and advertising. The manufacturer must also give a cumulative annual history of average wholesale price and WAC increases.	Rep. Kelly Morrison (D)
MN	HF 743	Referred to House Commerce Committee	Pharmacy Benefit Manager	This measure prohibits a health plan from requiring an enrollee to pay a copayment for a prescription drug at the point of sale that is greater than the lesser of the allowable claim amount the pharmacy will receive from the plan or pharmacy benefit manager, or the amount an individual would pay at the pharmacy without using insurance.	Rep. Kristin Bahner (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

MN	HF 1523/SF 1734	Amended, passed House Health and Human Services Committee; referred to House Ways and Means Health and Human Services Finance Division/Referred to Senate Health and Human Services Finance and Policy Committee	Volume Purchasing	<p>This measure authorizes the Commissioner of Human Services to establish a prescription drug purchasing program that will:</p> <ul style="list-style-type: none"> -Make drugs available at the lowest possible cost to participants; -Promote health; -Maintain a list of drugs recommended as the most effective prescription drugs at the best prices; -Administer drug benefits for medical assistance and MinnesotaCare; and -Adjudicate pharmacy claims. <p>The commissioner will set the terms and conditions for pharmacies to participate in the program.</p>	Rep. Hunter Cantrell (D), Sen. John Hoffman (D)
MN	HF 2414/SF 2452	Became special session SF 12	Transparency	<p>This measure requires an annual report that details the state's effectiveness in promoting transparency in pharmaceutical pricing for the state and other payers, enhancing the understanding of pharmaceutical spending trends, and assisting the state in the management of pharmaceutical costs. This measure also limits cost-sharing requirements for prescription insulin drugs once the deductible is met.</p> <p>This measure requires the Human Services Commissioner to implement an insulin assistance program. The program will pay participating pharmacies for insulin that is dispensed by a participating pharmacy and maintain an up-to-date list of eligible individuals and make the list available to participating pharmacies. Eligible individuals must have a family income that is equal to or less than 400% of the federal poverty guidelines and be uninsured or have no prescription drug coverage.</p>	Rep. Tina Liebling (D), Sen. Michelle Benson (R)
MN	HF 2518	Referred to House Commerce Committee	Transparency	This measure requires that each manufacturer of a prescription drug that has a wholesale acquisition cost of \$10,000 or more annually must file a report with the Commissioner of Health. The report must include information will include cost information, including marketing and advertising costs.	Rep. Jeremy Munson (R)
MN	HF 2819	Referred to House Taxes Committee	Other	This measure imposes an excess prices tax on prescription drugs. The amount of the tax has not yet been established. Under this bill, manufacturers and wholesalers will annually submit the number of units of each drug sold in the state during the year to the revenue commissioner. "Excess price amount" means the difference between the manufacturer's adjusted average manufacturer price of a prescription drug and the indexed average manufacturer's price of a drug for a certain year.	Rep. Michael Howard (D)
MN	SF 67/HF 723	Referred to Senate Health and Human Services Finance and Policy Committee/Referred to House Health and Human Services Policy Committee	Pharmacy Benefit Managers	This measure prohibits a pharmacy benefit manager from prohibiting or penalizing a pharmacy or pharmacist for informing the covered person about the cost of the prescription or about any therapeutically equivalent alternative medications.	Sen. Scott Jensen (R), Rep. Steve Elkins (D)
MN	SF 237/HF 149	Referred to Senate Health and Human Services Finance and Policy Committee/Amended, passed House Commerce Committee	Pharmacy Benefit Managers	This measure prohibits a pharmacy benefit manager from prohibiting or penalizing a pharmacy or pharmacist from informing a patient about the out-of-pocket price for a drug. This measure also requires a pharmacist, when dispensing a prescription, to disclose the net amount the pharmacy will receive from all sources for dispensing the drug.	Sen. Scott Jensen (R), Rep. Kristin Bahner (D)
MN	SF 353/HF 1668	Referred to Senate Health and Human Services Finance and Policy Committee/Referred to House Commerce Committee	Cost Review (Rate Setting)	This measure creates the Prescription Drug Affordability Commission. Under this bill, drug manufacturers must notify the commission if they increase the wholesale acquisition cost (WAC) of a brand-name drug or biologic by more than 10% or by more than \$10,000 during any 12-month period, or if they intend to introduce a brand name drug to market with a WAC of \$30,000 per calendar year. For generic drugs, a manufacturer must notify the commission if the WAC increases by more than 25% or \$300 in an 12-month period. All manufactures must notify the commission of increases at least 30 days before an increase takes effect, along with a justification for the increase. The chair of the commission may initiate a review of the cost of a drug, and the commission will determine whether the drug will lead to excess costs on the health care system. If the commission finds that spending on the drug creates excessive costs for consumers, the commission will establish a maximum level of reimbursement.	Sen. Scott Jensen (R), Rep. Laurie Pryor (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

MN	SF 364/HF 284	Referred to Senate Health and Human Services Finance and Policy Committee/Amended, passed House Health and Human Services Policy; referred to House Judiciary, Finance and Civil Law Division	Cost Review (Rate Setting)	This measure authorizes the Commissioner of Health to review costs for insulin products sold in Minnesota to determine if the cost is excessive. Under this bill, each manufacturer of an insulin product must report the wholesale acquisition cost for each insulin product offered for sale in the state. If the commissioner finds that spending on an insulin product is excessive, the commissioner will establish a maximum level of reimbursement that must not create more than 50% net profit for the manufacturer.	Sen. Matt Little (D), Rep. Laurie Halverson (D)
MN	SF 366/HF 289	Referred to Senate Health and Human Services Finance and Policy Committee/Amended; passed House Commerce Committee; passed House Health and Human Services Policy; referred to House Ways and Means Committee Health and Human Services Finance Division	Transparency	This measure requires the Commissioner of Health to compile a list of essential diabetes medications. From the list, the commissioner must also compile a list of diabetes medications that have been subject to an increase in the wholesale acquisition cost of a percentage equal to or greater than the percentage increase in the Consumer Price Index Medical Care Component during the previous year or twice the percentage increase in the previous two years. Under this bill, manufacturers of drugs included on the commissioner's list must disclose pricing information, including the aggregate amount of all rebates the manufacturer provided to pharmacy benefit managers (PBM), as well as a justification for the price increase. This measure also requires PBMs to submit a report to the commissioner regarding rebates.	Sen. Matt Little (D), Rep. Alice Mann (D)
MN	SF 495	Referred to Senate State Government Finance and Policy and Elections Committee	Importation	This measure establishes a wholesale Canadian drug importation program. State and local government employee health care programs, as well as state health care programs and health plan companies, will be able to enter into an agreement with a pharmacy benefit manager to negotiate prices and administer contracts with Canadian pharmacies.	Sen. Carla Nelson (R)
MN	SF 841	Referred to Senate Health and Human Services Finance and Policy Committee	Pharmacy Benefit Manager	This bill requires licensure for pharmacy benefit managers (PBMs). This measure also requires that each PBM provide to a covered entity all financial and utilization information requested by the covered entity relating to the provision of benefits to covered individuals through that covered entity and, including all rebates and discounts from drug manufacturers. This measure also requires PBMs to disclose pricing information to consumers.	Sen. John Marty (D)
MN	SF 1006/HF 1257	Referred to Senate Health and Human Services Finance and Policy Committee/Passed House Health and Human Services Policy Committee; referred to House Ways and Means Committee Health and Human Services Finance Division	Pharmacy Benefit Manager	This bill allows health plans to change their formularies midyear to remove a brand drug from its formulary or move a brand drug to a new cost-sharing tier if a generic equivalent is approved.	Sen. Carla Nelson (R), Rep. Hunter Cantrell (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

MN	SF 1098/HF 1246	Passed Senate Health and Human Services Finance and Policy Committee, referred to Senate Judiciary and Public Safety Finance and Policy Committee/passed House Judiciary, Finance and Civil Law Division, referred to House Health and Human Services Finance Division	Transparency	This measure requires drug manufacturers to submit a report to the Commissioner of Health for every prescription drug priced more than \$40 for a course of therapy, whose price increases by more than 10% in a 12-month period or more than 16% in a 24-month period. Notice must be given to the commissioner at least 60 days before the planned increase. For every new brand-name drug priced over \$5,000 for a 30-day supply or a generic that is price over \$200 for a 30-day supply, the manufacturer must notify the commissioner within 60 days of introduction.	Sen. Julie Rosen (R), Rep. Kelly Morrison (D)
MN	SF 1184	Referred to Senate Health and Human Services Finance and Policy Committee	Importation	This measure instructs the Commissioner of Human Services to develop a wholesale drug importation program to make discounted prescription drugs imported from Canada available to Minnesotans.	Sen. Matt Little (D)
MN	SF 1640	Referred to Senate Health and Human Services Finance and Policy	Transparency	This measure creates the Prescription Drug Price Transparency Act. This bill requires that for every drug priced more than \$40 for a course of therapy, whose price increases by more than 10% in a 12-month period or more than 16% in a 24-month period, the manufacturer must report to the Health Commissioner at least 60 days in advance of the increase certain pricing information. For every new brand-name drug priced over \$500 for a 30-day supply or for a generic drug priced over \$200, manufacturers must provide pricing information as well.	Sen. Rich Raheem (R)
MN	SF 1907/HF 743	Referred to Senate Commerce and Consumer Protection Finance and Policy Committee/amended, passed House Commerce Committee, referred to House Health and Human Services Finance Division	Other	This measure stipulates that a health plan that provides drug coverage shall not require an enrollee to pay a copayment for a prescription drug at the point of sale that is greater than the lesser of the allowable claim amount the pharmacy dispensing the drug will receive from the health plan company or pharmacy benefit manager or the amount an individual would pay at the pharmacy for the drug if the individual did not have insurance.	Sen. Scott Jensen (R), Rep. Kristin Bahner (D)
MN	SF 3031	Referred to House Commerce Committee	Other	This measure requires group purchasers and pharmacy benefit managers to use a real-time prescription benefit tool that complies with the National Council for Prescription Drug Programs Real-Time Prescription Benefit Standard and that, at a minimum, notifies a prescriber: (1) if a prescribed drug is covered by the patient's group purchaser or pharmacy benefit manager; (2) if a prescribed drug is included on the formulary or preferred drug list of the patient's group purchaser or pharmacy benefit manager; (3) any patient cost sharing for the prescribed drug; (4) if prior authorization is required for the prescribed drug; and (5) a list of any available alternative drugs that are in the same class as the drug originally prescribed and for which prior authorization is not required. Under this bill, a health plan must make its formulary information available by electronic means and, upon request, in writing, at least 30 days prior to annual renewal dates. A health plan company may remove a brand-name drug from its formulary or place a brand-name drug in a benefit category that increases an enrollee's cost only upon the addition to the formulary of a generic or multi-source brand-name drug rated as therapeutically equivalent at a lower cost to the enrollee.	Rep. Hunter Cantrell (D)
MS	HB 474	Referred to House Insurance Committee	Coupons/Cost Sharing	This measure caps the cost-sharing price or copay of insulin at \$100 for a 30-day supply. This measure also requires the attorney general to investigate insulin pricing to determine whether additional consumer protections are needed.	Re. William Arnold (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

MS	HB 532	Referred to House Drug Policy Committee	Transparency	<p>This measure requires the state's attorney general to compile a list of essential diabetes drugs that includes wholesale acquisition costs (WAC). The attorney general must also compile a list of essential diabetes drugs that have been subject to an increase in the WAC of a percentage equal to or greater than the percentage increase in the consumer price index during the immediate preceding year, or twice the percentage increase in the consumer price index in the immediate preceding two years. Any manufacturer with a drug on these lists must submit cost information. Manufacturers of drugs on the increase list must submit a justification for the price increase.</p> <p>This measure also requires pharmacy benefits managers to report rebate information.</p>	Rep. Jarvis Dortch (D)
MO	HB 1440	Introduced	Importation	<p>This measure allows for the importation of a prescription drug for personal use, so long as the patient has a valid prescription from a prescriber.</p>	Rep. Steve Helms (R)
MO	HB 1910	Introduced	Cost Review (Rate Setting)	<p>annually a report with the commission that discloses rebate information and that each. Health carriers must also submit annual reports that detail the 25 most frequently prescribed drugs, the 25 outpatient drugs that the plan covered at the greatest cost and the 25 drugs that experienced the greatest year-over-year increase in cost. Carriers must also submit a certification that they accounted for all rebates in calculating the premium for health benefit plans.</p> <p>This measure also requires drug manufacturers to notify the commission if they have filed a new drug application or biologics/biosimilars application. This bill gives the commission the authority to review each manufacturer of a pipeline drug that may have a significant impact on state expenditures for outpatient drugs.</p> <p>This measure requires brand manufacturers to notify the commission if the wholesale acquisition cost (WAC) is increasing by more than 10 percent or by more than \$10,000 or if the manufacturer intends to introduce a brand-name drug that has. WAC of \$30,000 per year. Manufacturers of generic or off-patent sole-source brand drugs must notify the commission if the manufacturer is increasing the WAC by more than 25% or by more than \$300 during any 12-month period. All manufacturers must include justifications for price increases that meet these thresholds.</p> <p>Before March 1, 2022, and annually thereafter, the commission must prepare a list of no more than 10 outpatient drugs that the commission determines are provided at substantial cost to the state. To be included on the list, the drug must have increased by at least 20% drug the preceding year or by at least 50% in the preceding two years. A drug on the list must also cost at least \$60.</p> <p>Under this measure, the public may request commission review of the cost of any drug reported. If the commission finds that the spending on a drug creates excess costs for carriers or consumers, the commission must establish the level of reimbursement that will be bill and paid among carriers, pharmacies, wholesalers and distributors.</p>	Rep. Doug Clemens (D)
MO	HB 1973	Introduced	Pharmacy Benefit Manager	<p>This measure requires pharmacy benefit managers to obtain a license from the Commerce and Insurance Department.</p>	Rep. Lynn Morris (R)
MO	HB 2412	Introduced	Pharmacy Benefit Manager	<p>This measure requires pharmacy benefit managers (PBMs) utilized by the Missouri consolidated health care plan to file annual transparency reports detailing aggregate rebate amounts.</p>	Rep. Steve Helms (R)
MO	SB 914	Introduced	Coupons/Cost Sharing	<p>This measure prohibits health benefit plans from imposing cost sharing on an enrollee in excess of \$100 per 30-day supply of a prescription insulin drug.</p>	Sen. Lauren Arthur (D)
MO	SB 971	Introduced	Pharmacy Benefit Manager	<p>This bill requires pharmacy benefit managers (PBMs) to obtain a license and prohibits the use of fraud or deception. This measure requires the PBM utilized by the Missouri consolidated health care plan to file an annual report containing rebate information. Under this bill, any entity that enters into a contract to reimburse a pharmacy for prescription drugs on behalf of another entity must define and apply the term "generic" with respect to prescription drugs, to mean any "authorized generic drug." Additionally, a PBM that contracts with a carrier or the state will owe a fiduciary to that entity. If a reimbursement by a PBM to a contracted pharmacy is below the pharmacy's cost to purchase the drug, the PBM must sustain an appeal and increase reimbursement to the pharmacy and other contracted pharmacies to cover the cost of purchasing the drug.</p>	Sen. David Sater (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

NE	LB 567	Referred to Health and Human Services Committee	Transparency	Under this bill, a manufacturer of a prescription drug with a wholesale acquisition cost (WAC) of more than \$40 for a course of therapy must provide notice to state purchasers if the increase in the WAC is more than 16% over the previous two years. Notice of the price increase must be given within 60 days of the planned increase and must be accompanied by pricing information. This measure also requires manufacturers to notify the Department of Administrative Services if they plan to introduce a new drug to market that exceeds the threshold set for a specialty drug under Medicare and to provide pricing information.	Sen. Adam Morefeld
NE	LB 1182	Introduced	Transparency	<p>This measure requires new drug application sponsors to submit to the Department of Health and Human Services written notice informing the department that such sponsor has filed with the US Food and Drug Administration (FDA) either a new drug application or a biologics license application for a biosimilar drug. Notice must be given within 60 days of the sponsor's receipt of an action from the FDA.</p> <p>This measure also allows the department to conduct a study of each manufacturer of a pipeline drug that, in the opinion of the Medicaid director, may have a significant impact on state expenditures. Manufacturers that are subjects of a study must submit certain information to the department.</p> <p>This measure additionally requires the Medicaid director to publish a list of no more than 10 drugs that are provided at a substantial cost to the state or that are critical to public health. To be included on the list, the wholesale acquisition cost of a drug must have increased by at least 20% in a year or by 50% over three years. Manufacturers of drugs included on the list will be required to submit pricing information to the department.</p>	Sen. Justin Wayne (D)
NE	LB 1196	Referred to Banking, Commerce and Insurance Committee	Pharmacy Benefit Manager	<p>This measure prohibits an insurer from requiring a covered individual to make a payment for a prescription drug in an amount that exceeds applicable cost-sharing or the amount an individual would pay without insurance. This measure also prohibits a pharmacy benefit manager (PBM) from retroactively denying a claim and patient steering by PBMs. Under this measure, a PBM cannot reimburse a pharmacy in an amount less than the PBM would reimburse an affiliate. This measure further prohibits a PBM from conducting spread pricing. This measure lays out requirements for how often PBMs must update maximum allowable cost lists and the procedure by which a pharmacy can appeal a reimbursement.</p> <p>This measure also requires carrier to include any cost-sharing amounts paid on behalf of enrollees by another person when calculating an enrollee's contribution to any applicable cost-sharing requirement. Under this bill, health plans can only offer plans that do not require an enrollee to pay a deductible for drugs and provide that the amount of cost-sharing paid by an enrollee does not exceed the amount of the copayment or coinsurance specified in the summary of benefits.</p>	Sen. Morfeld (D)
NH	HB 717	Referred to House Commerce and Consumer Affairs Committee	Coupons/Cost Sharing	This measure prohibits prescription drug manufacturers from offering coupons or discounts to cover insurance copayments or deductibles if a lower cost generic is covered under the individual's health insurance.	Rep. Garrett Muscatel (D)
NH	HB 1280	Referred to House Commerce and Consumer Affairs Committee	Coupons/Cost Sharing	This measure caps the cost-sharing price or copay of insulin at \$100 for a 30-day supply.	Rep. Garrett Muscatel (D)
NH	HB 1697	Referred to House Commerce and Consumer Affairs Committee	Coupons/Cost Sharing	This measure prohibits pharmacies from accepting manufacturer discounts as payment on behalf of a person. This does not apply to branded prescription drugs without generic equivalents. This measure also prohibits the use of manufacturer discounts for a drug if the active ingredients of the drug are contained in products regulated by the US Food and Drug Administration and are available without prescription at a lower cost. This prohibition does not apply to a single-tablet drug regimen for the treatment or prevention of HIV/AIDS.	Rep. Ed Butler (D)
NH	SB 63	Passed House	Pharmacy Benefit Manager	This measure requires that all rebates remitted by or on behalf of a pharmaceutical manufacturers, or to a pharmacy benefits manager under contract with an insurer, must be either remitted directly to an enrollee at the point of sale or retained by the insurer to off set premium costs.	Sen. Jon Morgan (D)
NH	SB 260	Amended, passed Senate Finance Committee	Other	This measure directs the Department of Health and Human Services to develop a prescription drug assistance program to pay out-of-pocket prescription drug costs for seniors who have reached the gap in standard Medicare Part D coverage. This will be a one-year long pilot program.	Sen. Dan Feltes (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

NH	SB 688	Referred to Senate Commerce Committee	Price Gouging	This measure prohibits pharmaceutical manufacturer or wholesale distributor from engaging in price gouging of an essential off-patent or generic drug. This bill requires the Commissioner of Health and Human Services to notify the attorney general of an increase in the price of an essential off-patent or generic drug if the price increase would result in a price increase of 50% or more, or if the cost of a 30-day supply would cost more than \$80.	Sen. Martha Fuller Clark (D)
NJ	A 653	Referred to Assembly Financial Institutions and Insurance Committee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can required a covered patient with diabetes to pay for a 30-day supply of insulin at \$100.	Rep. John Armato (D)
NJ	A 687	Referred to Assembly Health Committee	Other	This measure requires health benefits plans that include prescription benefits, including Medicaid, to provide coverage for pre-exposure prophylaxis (or PrEP) PrEP and PEP without any prior authorization or step therapy requirements.	Asm. Valerie Vainieri Huttle (D)
NJ	A 954/S 1729	Referred to Assembly Financial Institutions and Insurance Committee/Filed	Coupons/Cost Sharing	This measure places a \$100 cap on the amount paid by a covered person for the purchase of a 30-day supply of insulin drugs, regardless of the type of insulin needed to fill the prescription. This measure also requires the Division of Consumer Affairs to investigate the pricing of insulin to determine whether additional consumer protections are needed.	Asm. Robert Karabinchak (D), Sen. Joseph Lagana (D)
NJ	A 955	Referred to Assembly Financial Institutions and Insurance Committee	Pharmacy Benefit Manager	This measure prohibits pharmacy benefit managers (PBMs) from requiring covered persons to use mail service pharmacies.	Asm. Robert Karabinchak (D)
NJ	A 1028/ S 1253	Referred to Assembly Human Services Committee/Referred to Senate Health, Human Services and Senior Citizens Committee	Pharmacy Benefit Manager	This measure requires prescription drug services covered under Medicaid to be provided through a fee-for-service delivery system. Additionally, this bill requires that the reimbursement for covered drugs be based on the lower of the National Average Drug Acquisition Cost, the federal upper limit, the state maximum allowable cost, the state submitted ingredient cost, or the provider's usual and customary charge.	Asm. Joann Downey (D), Sen. Vin Gopal (D)
NJ	A 1258/S 1210	Referred to Assembly State and Local Governments Committee/Referred to Senate State Government, Wagering, Tourism and Historic Preservation Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) under contract with the State Health Benefits Program (SHBP) and the School Employees' Health Benefit Program (SEHBP) to report prices paid to pharmacies and the amounts charged to SHBP and SEHBP.	Asm. Gary Schaer (D), Sen. Joseph Cryan (D)
NJ	A 1259/S 249	Referred to Assembly Human Services Committee/Passed Senate	Pharmacy Benefit Manager	This measure requires a pharmacy benefit manager (PBM) providing services within Medicaid to disclose certain information to the Department of Human Services. Under this bill, any contract entered into by a managed care organization (MCO) that has contracted with the Division of Medicaid Assistance and Health Services would require the PBM to disclose all sources of incomes (including pricing discounts and rebates), all ingredient costs and dispensing fees made by the PBM to pharmacies, and the PBM's payment model for administrative fees.	Asm. Gary Schaer (D), Sen. Troy Singleton (D)
NJ	A 1477/S 1142	Referred to Assembly Health Committee/Referred to Senate Health, Human Services and Senior Citizens Committee	Cost Review (Rate Setting)	<p>This bill establishes the Prescription Drug Review Commission, which will be tasked with developing a list of critical prescription drugs for which manufacturers will be required to report certain information concerning development, production, and marketing costs. If the commission determines that a drug is priced excessively high, it will have the authority to establish a maximum price for the drug in the state.</p> <p>In developing the list of critical drugs, the commission must consider the cost of the drug in the state, utilization, the availability and cost of therapeutically equivalent treatments, and other factors. The commission must update the list at least once every three years. For each drug on the list, manufacturers must report information concerning the total cost of production, research and development costs, marketing costs, etc.</p> <p>The commission must prepare an annual report on drug prices and their role in overall health care spending in the state based on information received from manufacturers.</p>	Asm. Paul Moriarty (D), Sen. Joseph Vitale (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

NJ	A 2222	Referred to Assembly Financial Institutions and Insurance Committee	Pharmacy Benefit Manager	This measure requires carriers to pass prescription drug savings on to consumers. Under this bill, all compensation paid by a manufacturer to a pharmacy benefit manager (PBM) must be remitted to and retained by the carrier and must be used by the carrier to lower premiums for enrollees. Carriers will be required to file a report demonstrating how they have complied with these requirements.	Asm. John McKeon (D)
NJ	S 234	Referred to Senate Health, Human Services and Senior Citizens Committee	Cost Review (Rate Setting)	<p>This bill establishes the Prescription Drug Review Commission, which will be tasked with developing a list of critical prescription drugs for which manufacturers will be required to report certain information concerning development, production, and marketing costs. If the commission determines that a drug is priced excessively high, it will have the authority to establish a maximum price for the drug in the state.</p> <p>In developing the list of critical drugs, the commission must consider the cost of the drug in the state, utilization, the availability and cost of therapeutically equivalent treatments, and other factors. The commission must update the list at least once every three years. For each drug on the list, manufacturers must report information concerning the total cost of production, research and development costs, marketing costs, etc.</p> <p>This measure also prohibits manufacturers and wholesale distributors from engaging in price gouging in the sale of an essential off-patent generic drug or biologic. In this bill, an "essential off-patent drug" means any product made available in the state that appears on the current Model List of Essential Medicines adopted by the World Health Organization. The director of the Division of Consumer Affairs in the Department of Law and Public Safety may notify the attorney general of any increase in the price of an essential off-patent or generic drug whenever the price increase would result in an increase of 50% or more in the wholesale acquisition cost (WAC) in one year and so long as the WAC of that drug is more than \$80 for a 30-day supply. The attorney general can then require a manufacturer or wholesaler that has engaged in price gouging to make the drug available in the state at a price that does not exceed the price before the violation.</p> <p>This measure also establishes prescription drug pricing disclosure requirements. Under this bill, pharmacy benefit managers (PBMs) are required to disclose, in the contract entered into between the purchaser and the PBM, the methodology and sources used to determine multiple source generic drug and biologic pricing. This bill also requires PBMs to disclose to purchasers whether the multiple source generic pricing list used to bill the purchaser is the same as the list used to reimburse pharmacies. If those lists are not the same, the difference between the amount paid to the pharmacy and the amount charged to the purchasers must be disclosed.</p>	Sen. Troy Singleton (D)
NJ	S 526/A 1669	Amended, referred to Senate Budget and Appropriations Committee/Referred to Assembly Financial Institutions and Insurance Committee	Coupons/Cost Sharing	This measure provides that coverage of insulin shall not be subject to any deductible, and no copayment or coinsurance for the purchase of insulin can exceed \$50 per 30-day supply. This bill also requires every manufacturer of an insulin produce to submit pricing information for insulin products.	Sen. Joseph Vitale (D), Asm. Annette Quijano (D)
NJ	S 1765	Filed	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) providing services within Medicaid to implement pass-through pricing models and to disclose certain information to the Department of Human Services and managed care organizations.	Sen. Vin Gopal (D)
NJ	S 887	Referred to Senate Health, Human Services and Senior Citizens Committee	Pharmacy Benefit Manager	This measure requires the Department of Human Services to transition Medicaid prescription drug services from managed care to fee-for-services. This measure also provides for the procurement by the state of a pharmacy benefit manager to administer Medicaid fee-for-service prescription drug services. This measure also requires the creation of a technology platform that can conduct a reverse auction.	Sen. Stephen Sweeney (D)
NJ	S 1046	Referred to Senate Commerce Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) from requiring a pharmacy to purchase a specialty drug directly from the PBM as a condition for participating in a PBM's network contract or for any other reason. This bill also requires PBMs to submit quarterly reports detailing the aggregate amounts paid by the PBM to drug wholesalers or manufacturers, the aggregate amounts charged by the PBM to purchasers for providing that drug to pharmacies and the aggregate amount paid by the PBM to pharmacies for dispensing that drug.	Sen. Joseph Cryan (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

NJ	S 1066/A 2418	Referred to Senate Health, Human Services and Senior Citizens Committee/Filed	Cost Review (Rate Setting)	<p>This measure establishes the Prescription Drug Affordability Board in the Division of Consumer Affairs, which will be charged with protecting residents from the high costs of prescription drugs. The board is required to conduct a study of the entire pharmaceutical distribution and payment system in the state, as well as policy options being used in other states and countries to lower the list price of drugs, including establishing upper payment limits, using a reverse auction marketplace, allowing importation from other countries, and implementing a bulk purchasing process. The board must also study the operation of the generic drug market.</p> <p>Under this bill, the board must collect and review publicly-available information regarding prescription drug product manufacturers, health benefits plan carriers, wholesale distributors, and pharmacy benefits managers. The board can also establish methods for collecting additional data. The board will use information collected to identify drugs that have a significantly high wholesale acquisition cost (WAC) or that have a WAC that has increased by a significant percentage over a 12-month period, as well as other prescription drug products the board determines may create affordability issues. The board will then conduct a cost review of certain drugs to determine whether it has or will lead to affordability challenges. If the board determines that it is in the best interest of the state to develop a process to establish upper payment limits (UPLs) for, or allow importation from other countries of, prescription drug products that have led or will lead to an affordability challenge, the board will be required to draft a plan of action for implementing the process that includes the criteria the board will use to establish UPLs or consideration of certain cost and logistical factors that may affect importations from other countries.</p> <p>The board's action plan must be submitted to the legislature for approval no later than 24 months after the bill goes into effect. The legislature will then decide whether or not to approve the plan.</p>	Sen. Troy Singleton (D), Sen. John McKeon (D)
NJ	S 1067	Referred to Senate Health, Human Services and Senior Citizens Committee	Volume Purchasing	<p>This measure requires the director of the Division of Purchase and Property to review all state pharmaceutical purchasing arrangements, contracts, and initiatives and consider all options to maximize the state's bargaining power with regard to pharmaceutical products. Under this bill, the director must create and maintain a list of drugs and devices that may appropriately be prioritized for bulk purchasing initiatives or reexamined for potential renegotiation with the manufacturer. The director's determination as to which drugs are to be prioritized will include the 25 prescription drugs that represented the highest cost to the state in the preceding calendar year. The director will use that list to implement bulk purchasing arrangements for high-priority drugs.</p> <p>The director must also establish processes for county and local governments, as well as private purchasers, including small businesses, health benefits plans, and self-insured entities and individuals, to benefit from state bulk pharmaceutical purchasing agreements.</p>	Sen. Troy Singleton (D)
NM	HB 292	Amended; passed House State Government, Elections and Indian Affairs Committee	Coupons/Cost Sharing	<p>This measure caps the total amount an insured is required to pay for prescription insulin drugs at \$50 per 30-day supply, regardless of the amount, number of prescription drugs or types of insulin prescribed.</p>	Rep. Micaela Cadena (D)
NM	SB 1	Passed House Health and Human Services Committee	Importation	<p>This measure requires the Department of Health to design a wholesale prescription drug importation program that complies with federal requirements. The department must submit a formal request to create the program to the US Secretary of Health and Human Services by Dec. 15, 2020.</p>	Sen. Mary Kay Papen (D)
NY	AB 73	Referred to Assembly Health Committee	Pharmacy Benefit Managers	<p>This measure prohibits prescribers, pharmacies, pharmacists, pharmacy benefit managers, or health plans from disclosing or selling any individual's identifying information for the purpose of marketing any drug.</p>	Asm. Kevin Cahill (D)
NY	AB 2969	Referred to Assembly Insurance Committee	Pharmacy Benefit Manager	<p>This bill allows health plans to change their formularies midyear to remove a brand-name drug from its formulary or move a brand-name drug to a new cost-sharing tier if a generic-equivalent drug is approved.</p>	Asm. Crystal Peoples-Stokes (D)
NY	AB 5724	Enacting clause stricken	Other	<p>This measure would prohibit any form of group health insurance policy that categorizes prescription medication based on specific disease or specific cost and charges a cost-sharing percentage for such prescription medication.</p>	Asm. Michele Titus (D)
NY	AB 6056	Referred to Assembly Health Committee	Pharmacy Benefit Manager	<p>This measure requires pharmacies to provide customers directly with the retail price (before insurance) of a prescription drug, in writing and electronically prior to purchase.</p>	Asm. Gary Pretlow (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

NY	AB 7196/SB 5169	Amended; referred to Assembly Consumer Affairs and Protection Committee/Amended; referred to Senate Consumer Protection Committee	Other	This measure requires prescription drug manufacturers to notify the attorney general of agreements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications. Within 30 days of receiving notice, the attorney general must share the information with the drug utilization review board, all Medicaid managed care plans, health carriers and pharmacy benefit managers doing business in the state. The attorney general will also post all notices on the department website.	Asm. Michael DenDekker (D), Sen. Alessandra Biaggi (D)
NY	AB 7588/SB 5682	Referred to Assembly Higher Education/Referred to Senate Health Committee	Importation	This measure creates a wholesale prescription drug importation that will comply with federal standards and regulations.	Asm. Richard Gottfried (D), Sen. James Skoufis (D)
NY	AB 7922	Referred to Assembly Health Committee	Transparency	This measure requires the Commissioner of Health to include in annual reports information regarding the cost and increase in cost of the 10 prescription drugs on which the state expends the most money and which have had wholesale acquisition cost increases of 50% in the past five years or 10% in the past year.	Asm. Linda Rosenthal (D)
NY	A 8246/S 6303	Referred to Assembly Insurance Committee; Referred to Assembly Insurance Committee	Coupons/Cost Sharing	This measure requires any third-party payments, financial assistance, or discounts made on behalf of an enrollee to be applied to the enrollee's cost-sharing requirements when calculating the enrollee's overall contribution to any out-of-pocket maximum or cost-sharing requirement.	Asm. Dick Gottfried (D), Sen. Gustavo Rivera (D)
NY	AB 9115	Referred to Assembly Insurance Committee	Other	This measure requires insurers and pharmacy benefit managers to provide coverage for off-label drug usage in certain circumstances.	Asm. Melissa Miller (R)
NY	AB 9507/ SB 7507	Referred to Assembly Ways and Means Committee/Referred to Senate Finance Committee	Pharmacy Benefit Manager	These provisions are included in the state health and mental hygiene budget for the coming fiscal year. This measure requires pharmacy benefit managers (PBMs) to register with the Superintendent of Insurance, as well as obtain a license. This measure also requires PBMs to submit an annual report to the superintendent regarding pricing discounts and rebates.	Budget Bill
NY	S 141	Referred to Senate Consumer Protection Committee	Price Gouging	This measure prohibits a pharmaceutical manufacturer or wholesaler from selling pharmaceuticals for an amount that represents an unconscionably excessive price, which will be determined by a court. The court shall base its determination on whether the amount of the excess price is unconscionably extreme or whether there was an exercise of unfair leverage or unconscionable means. Proof that a violation of this measure has occurred will require evidence that either the amount charged represents a gross disparity between the market price of the pharmaceutical and the price of the same pharmaceutical over the previous six months before the price change, or the amount charged grossly exceeded the price at which the pharmaceuticals were readily obtainable by other purchasers. This bill gives the New York Attorney General the ability to penalize a manufacturer with a fine of up to \$1 million.	Sen. David Carlucci (D)
NY	SB 1705/AB 2970	Referred to Senate Insurance Committee/Referred to Assembly Insurance Committee	Pharmacy Benefit Managers	This measure requires transparency from pharmacy benefit managers (PBMs). Under this bill, PBMs will be required to submit an annual report that contains information regarding the wholesale acquisition cost for each drug on its formulary, the amount of rebates and discounts that were passed through to a covered entity, and the amounts of any reimbursements that PBM pays the contracting pharmacies. Aggregate information will be made available to consumers each year in February.	Sen. Luis Sepulveda (D), Asm. Felix Ortiz (D)
NY	SB 2087	Referred to Senate Health Committee	Pharmacy Benefit Managers	This measure establishes a fiduciary duty for pharmacy benefit managers (PBMs) to health plans. This measure also prohibits PBM contracts from prohibiting pharmacists from disclosing pricing information to consumers or offering the consumer a therapeutic equivalent. This measure also prohibits a PBM from collecting a copayment that exceeds the total submitted charges by the pharmacy for which the pharmacy is paid. This measure also requires PBMs to report annually on the aggregate amount of rebates received from manufacturers for health plans.	Sen. Gustavo Rivera (D)
NY	SB 5942/AB 8253	Referred to Senate Health Committee/Referred to Assembly Health Committee	Transparency	This measure requires a manufacturer of a prescription drug with a wholesale acquisition cost (WAC) of more than \$40 for a course of therapy to notify the Drug Utilization Review Board if the increase in the WAC of the drug is more than 10%. Notice to the board must be given at least 60 days before the planned increase.	Sen. Julia Salazar (D), Asm. Linda Rosenthal (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

NY	SB 5943	Referred to Senate Health Committee	Transparency	This measure requires the Commissioner of Health to include in annual reports information regarding the cost and increase in cost of the 10 prescription drugs on which the state expends the most money and which have had certain costs increase. Manufacturers on the list will be required to submit pricing information.	Sen. Julia Salazar (D)
NY	SB 6103	Referred to Senate Health Committee	Other	This measure prohibits a drug manufacturer from presenting a regulated advertisement in the state, unless the advertisement meets the requirements concerning misbranded drugs and devices and prescription drug advertising of federal law and regulations. This measure also requires a manufacturer that is required to report marketing costs to post information concerning any clinical trials.	Sen. David Carlucci (R)
NY	SB 6274	Referred to Senate Insurance Committee	Pharmacy Benefit Manager	This measure establishes registration and licensing requirements for pharmacy benefit managers (PBMs). This measure also prohibits PBMs from restricting pharmacies or pharmacists from disclosing cost information to enrollees at the point of sale. Under this bill, a PBM cannot charge or collect from an individual a copayment that exceeds the total submitted charges by the pharmacy for which the pharmacy is paid.	Sen. Neil Breslin (D)
NY	SB 6297/AB 8165	Referred to Assembly Insurance Committee/Referred to Assembly Insurance Committee	Pharmacy Benefit Manager	This measure requires that any contract entered into by a health insurer for the provision of pharmacy benefit management services must be based on a pass-through pricing model. This bill also prohibits the use of spread pricing. In addition, payments to the PBM will be limited to the actual ingredient costs, dispensing fees paid to pharmacies and an administrative fee that covers the cost of providing pharmacy benefit management services. The PBM must identify all sources and amount of income, including any price discounts or rebates. Under this measure, PBMs must disclose the Insurance Department and to the health care plan the sources of income identified.	Sen. James Skoufis (D), Asm. Kevin Cahill (D)
NC	HB 534/SB 632	Referred to House Insurance Committee/Referred to Committee on Rules and Operations of the Senate	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to obtain licensure from the Department of Insurance. This measure also prohibits a PBMs from penalizing a pharmacy or pharmacist for disclosing cost information to a consumer. Under this bill, a PBM cannot charge an insured a copayment that exceeds the total submitted charges by the network pharmacy, the contracted copayment amount, or the amount a consumer would pay without insurance. Additionally, this bill requires that when calculating an insured's overall contribution to any out-of-pocket maximum, an insurer must include any amounts paid on behalf of an enrollee. This measure also requires that PBMs disclose to health plans and providers any difference between the amount paid to a pharmacy and the amount charged to the plan. PBMs must also submit an annual report to the Insurance Commissioner the aggregate amount of all rebates received from manufacturers, including the amount that was not passed through to payers or insurers.	Rep. Wayne Sasser (R), Sen. Danny Britt (R)
NC	SB 432	Substituted; referred to House Committee on Finance	Pharmacy Benefit Manager	This measure requires a pharmacy benefits manager (PBM) to obtain a license from the Department of Insurance before operating in the state. This measure also requires that amounts paid on behalf of an insured by another person count toward any out-of-pocket maximum or cost-sharing requirement under the health benefit plan. This bill prohibits the retroactive denial or reduction of a claim for pharmacist services. This measure requires PBMs to establish an administrative appeals process for a pharmacists.	Sen. Deanna Ballard (R)
NC	SB 658	Filed	Transparency	This measure requires manufacturers to notify all interested parties of an upcoming substantial price increase at least 60 days prior to the increase. Within 30 days of notification the manufacturer must disclose a justification for the price increase, the previous year's marketing budget for the drug, the date and price of acquisition, and a schedule or price increases for the drug for the previous five years. Under this bill, "substantial price increase" means any increase in the price charged by a manufacturer for a prescription drug that would have the impact of increasing a drug's cost by 10% or more over 12 months.	Sen. Mutjaba Mohammed (D)
OH	HB 63	Referred to House Health Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager from requiring cost sharing in an amount greater than the lesser of either the amount an individual would pay without coverage or the net reimbursement paid to the pharmacy for the drug by the issuer.	Rep. Scott Lipps (R)
OH	HB 385	Referred to House Health Committee	Other	This measure requires the attorney general to investigate insulin pricing and prepare and submit a report.	Sen. Beth Liston (D)
OH	HB 387/SB 232	Referred to House Health Committee/Referred to Senate Finance Health and Medicaid Subcommittee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at \$100.	Rep. Beth Liston (D), Sen. Hearcel Craig (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

OH	HB 396	Referred to House Health Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) contracted with a Medicaid managed care organization from engaging in spread pricing. This measure also prohibits a PBM from directly or indirectly retroactively denying a claim or aggregate of claims after the claim or aggregate of claims has been adjudicated. This measure also prohibits PBMs from paying or reimbursing a pharmacy at an amount less than the national average drug acquisition cost. Additionally, this measure requires a PBM to report rebate information to the Superintendent of Insurance.	Rep. Tavia Galonski (D)
OH	HB 482/SB 263	Referred to House Health Committee/Introduced	Pharmacy Benefit Manager	This measure stipulates that a contract entered into between a health plan issuer and a 340B covered entity shall not contain any of the following provisions: (1) a reimbursement rate for a drug that is less than the national average drug acquisition cost rate for that drug; (2) a dispensing fee reimbursement amount that is less than the reimbursement amount provided to a terminal distributor of dangerous drugs; (3) a fee that is not imposed on a health care provider that is not a 340B covered entity; and (4) a fee amount that exceeds the fee amount for a health care provider that is not a 340B-covered entity.	Rep. Randi Clites (D), Sen. Bob Hackett (R)
OH	SB 14	Introduced	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager from requiring cost sharing in an amount greater than the amount an individual would pay for the drug if the drug were purchased without coverage.	Sen. Tina Maharath (D)
OH	SB 231	Referred to Senate Finance Health and Medicaid Subcommittee	Other	This measure requires the attorney general to investigate insulin pricing and prepare and submit a report.	Sen. Hearcel Craig (D)
OK	HB 1059	Referred to House Rules Committee	Pharmacy Benefit Managers	This measure prohibits a pharmacy benefit manager from prohibiting or penalizing a pharmacy or pharmacist for informing the covered person about the availability of alternative therapies or cost of the prescription. This measure authorizes a pharmacy or pharmacist to disclose information regarding the cost of a drug and to sell a more affordable alternative if one is available.	Rep. Marcus McEntire
OK	HB 1130	Referred to House Insurance Committee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at \$100.	Rep. Forrest Bennett (D)
OK	HB 2137	Referred to House Business and Commerce Committee	Pharmacy Benefit Managers	This measure requires every pharmacy benefit manager (PBM) to obtain a license from the Insurance Commissioner. This measure also allows a pharmacist to provide a consumer with drug pricing information and prohibits PBMs from prohibiting pharmacists from disclosing information to the Insurance Commissioner.	Rep. David Perryman (D)
OK	HB 2852	Referred to House Public Health Committee	Importation	This measure requires the Department of Health to create a wholesale Canadian drug importation program. This bill authorizes the department to establish a nominal fee per unit of drug to cover only costs necessary to administer the program.	Rep. Daniel Pae (R)
OK	HB 3737	Introduced	Coupons/Cost Sharing	This measure stipulates that the failure of a health insurer or pharmacy benefit manager (PBM) to include any amount paid on behalf of an enrollee by another person when calculating the enrollee's total contribution to an out-of-pocket maximum, deductible, copayment, coinsurance, or other cost-sharing requirements will be deemed an unfair claim settlement practice.	Rep. T.J. Marti (R)
OK	SB 940	Referred to Senate Health and Human Services Committee	Importation	This measure requires the Department of Health to work with the Health Care Authority to create a wholesale Canadian drug importation pilot program. The Health Care Authority will be responsible for identifying the five to 10 highly prescribed drugs through the state Medicaid program. The drugs identified will be imported from Canada.	Sen. Adam Pugh (R)
OK	SB 1082	Introduced	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at \$100.	Sen. Carri Hicks (D)
OK	SB 1158	Introduced	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at \$100.	Sen. Bill Coleman (R)
OK	SB 1171	Referred to Senate Retirement and Insurance Committee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at \$100.	Sen. George Young (D)
OK	SB 1521	Referred to Senate Retirement and Insurance Committee	Transparency	This measure requires drug manufacturers to submit annual reports to the insurance commission with the current wholesale acquisition cost information for all drugs sold in the state. The commissioner will make this information available on a website.	Sen. Marty Quinn (R)
OK	SB 1576	Referred to Senate Retirement and Insurance Committee	Coupons/Cost Sharing	This measure requires the Insurance Department to investigate the price of prescription insulin drugs. If necessary, the attorney general may issue a civil investigative demand requiring entities in the supply chain to submit information. The department must issue a public report detailing any findings by Nov. 1, 2021. This measure also requires health plans to cap the total amount that an insured is required to pay for insulin at \$100 per 30-day supply, regardless of the amount, type of number of prescriptions required.	Sen. Casey Murdock (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

OK	SB 1620	Referred to Senate Retirement and Insurance Committee	Transparency	This measure authorizes pharmacists to submit a request in writing from the patient for information on the specific allocation of the dollar amount of the retail price provided to the insurer, manufacturer, wholesale drug distributor, and pharmacy benefit manager for the drug being dispensed. The entities listed will have 30 days to provide the requested information. If the information is not provided to the pharmacist, a \$50 per day fine will be levied on any entity that failed to report.	Sen. Rob Standridge (R)
OK	SB 1722	Referred to Senate Retirement and Insurance Committee	Transparency	This measure requires a manufacturer to notify the Insurance Department if it is increasing the wholesale acquisition cost (WAC) of a brand name drug 20% per WAC unit during a year, or if it increases the WAC of a generic drug priced at \$10 per WAC unit by more than 20% during a year. This notice must be given at least 60 days prior to increase. Manufacturers must also notify the department if it intends to introduce a new drug that has a WAC of more than \$670 per WAC unit. That notice must also be provided 60 days prior to launch. This measure requires manufacturers of drugs that meet the thresholds above to report to the department all data elements specified in the NASHP model act. In line with the NASHP model, pharmacy benefit managers, wholesale drug distributors, and insurers must also report pricing information.	Sen. Carri Hicks (D)
OK	SB 1876	Referred to Senate Retirement and Insurance Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers to annually report rebate information to the Insurance Commissioner.	Sen. Paul Scott (R)
OK	SB 1881	Referred to Senate Health and Human Services Committee	Transparency	This measure requires the Insurance Department to compile annually a list of drugs the department determines to be essential for treating diabetes, along with a list of essential diabetes drugs that have been subject to an increase in the wholesale acquisition cost (WAC) of a percentage equal to or greater than the percentage increase in the Consumer Price Index (CPI) during the year before or twice the percentage increase in the CPI during the previous two years. Manufacturers of drugs on this list will be required to submit pricing information to the department.	Sen. Carri Hicks (D)
OK	SB 1912	Referred to Senate Health and Human Services Committee	Importation	This measure directs the Department of Health to design a wholesale drug importation program.	Sen. Rob Standridge (R)
OR	HB 4073	Referred to House Health Care Committee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at \$100.	Rep. Sheri Schouten (D)
OR	HB 4116	Referred to House Health Care Committee	Other	This measure requires health insurance policies to cover the cost of drugs prescribed for urgent medical conditions and for the cost of drugs prescribed and dispensed by pharmacists within their scope of practice.	Rep. Margaret Doherty (D)
OR	HB 4134	Referred to House Revenue Committee	Pharmacy Benefit Manager	This measure prohibits pharmacy benefit managers (PBMs) from including in a contract with a network pharmacy terms barring price increases to customers to offset the estimated amount of corporate activity tax paid by the pharmacy and attributable to the sale of prescription drugs.	Rep. Ron Noble (R)
OR	HB 4147	Referred to House Health Care Committee	Importation	This measure requires the Oregon Health Authority to design a program to import wholesale prescription drugs from Canada. This bill authorizes the administrator of the Oregon Prescription Drug Program to contract with a pharmacy benefit manager and to establish a state-managed wholesale or retail drug distribution or dispensing system.	Oregon Coalition
OR	SB 1535	Referred to Senate Health Care Committee	Transparency	This measure requires the Department of Consumer and Business Services to investigate methods for collecting information about rebates and markups used in the pharmaceutical supply chain and to report to interim legislative committees recommendations for collecting information. This bill also authorizes the department to access, use and disclose data from the All Payer, All Claims database. This measure also modifies the increase in the price of a prescription drug that triggers pharmaceutical manufacturers' obligation to report data under the Prescription Drug Price Transparency Act.	Sen. Elizabeth Steiner Hayward (D)
PA	HR 187	Referred to House Health Committee	Study	This resolution directs the Joint State Government Commission to conduct a study on prescription drug pricing and issue a report.	Rep. Eddie Pashinski (D)
PA	HB 568	Referred to House Insurance Committee	Transparency	This measure requires a manufacturer of a drug that has an average wholesale price of \$5,000 or more annually or per course of treatment or has an annual wholesale price that has increased by 50% or more over five years or by 25% in the past year to file an annual report with the Insurance Department that contains cost information. Manufacturers must include a description of patient prescription assistance programs in the report.	Rep. Anthony DeLuca (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

PA	HB 569	Referred to House Insurance Committee	Pharmacy Benefit Manager	This measure requires a pharmacy benefit manager (PBM) to disclose to a health insurer whether or not the PBM uses the same multiple-source generic list when billing a health insurer as it does when reimbursing a pharmacy. This bill also requires that if a PBM uses more than one multiple source generic list, the PBM must disclose to an insurer any difference between the amount paid to a pharmacy and the amount charged to the insurer.	Rep. Anthony DeLuca (D)
PA	HB 570	Referred to House Insurance Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager from restricting a pharmacist from disclosing information regarding the cost of a drug or the availability of any cheaper therapeutically alternatives.	Rep. Anthony DeLuca (D)
PA	HB 2212	Referred to House Health Committee	Cost Review (Rate Setting)	This measure establishes the Prescription Drug Affordability Board. The board must identify brand-name drugs that have a launch wholesale acquisition cost (WAC) of \$30,000 or a WAC increase of \$3,000 in a 12-month period, biosimilars that have a launch WAC that is not at least 15% lower than the referenced brand biologic, and generic drugs that have a WAC of \$100 or more and that increased by 200% over the preceding 12 months. The board has the authority to review any drugs identified to determine whether they create affordability challenges. If the board finds spending on a drug will lead to an affordability burden, the board must recommend or establish an upper payment limit that will apply to all purchases and payor reimbursements of the drug in the state. The Prescription Drug Affordability Stakeholder Group will help the board make determinations.	Rep. Dan Frankel (D)
PA	HB 941	Passed House Appropriations Committee; passed House; referred to Senate Health and Human Services Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) that contracts with a medical assistance managed care organization (MCO) from using a confidentiality provision that prohibits the disclosure of information to the MCO or Department of Human Services upon request. This measure also requires PBMs under contract with MCOs to report differences between the amount paid by the MCO to the PBM and the amount paid by the PBM to pharmacies. Under this bill, the department will reimburse pharmacies in the fee-for-service delivery system as follows: the lower of the National Average Drug Acquisition Cost (NADAC) per unit with a dispensing fee or the usual and customary charge for the drug dispensed. If the NADAC is not available, reimbursement will be the lower of the wholesale acquisition cost with a dispensing fee or the usual and customary charge.	Rep. Doyle Heffley (R)
PA	HB 943	Passed House Appropriations Committee; passed House; referred to Senate Health and Human Services Committee	Pharmacy Benefit Manager	This measure allows a pharmacist to provide a covered individual with information concerning the cost of a prescription drug, including the individual's cost share. A contract between a pharmacy and a pharmacy benefits manager cannot prohibit a pharmacist from disclosing cost information to a consumer.	Rep. Valerie Gaydos (R)
PA	HB 944	Passed House Appropriations Committee; passed House; referred to Senate Health and Human Services Committee	Pharmacy Benefit Manager	This measure provides for pharmacy benefits manager audits and defines obligations within the public assistance program.	Rep. Jonathan Fritz (R)
PA	HB 945	Amended; passed House Health Committee	Pharmacy Benefit Manager	This measure allows the Department of Human Services to prevent a medical assistance managed care organization from entering into any contract for pharmacy services with a pharmacy benefits manager (PBM) if the PBM has ownership interest in a pharmacy providing the services or if the pharmacy providing the services has an ownership interest in the PBM. Additionally, a PBM may not require that a beneficiary use the services of a specific pharmacy for any drug, including a specialty drug.	Rep. Stephen Barrar (R)
PA	HB 1042	Referred to House Health Committee	Study	This measure creates the Prescription Drug Pricing Task Force to study the pricing of prescription drugs and issue a report. The task force must issue the report within a year of the first meeting and must focus on factors contributing to high out-of-pocket costs, patient adherence and access to drugs, manufacturer costs for research and development, profit margins, financial assistance offered by manufacturers and the relationship between manufacturers and the state's medical assistance program.	Rep. Eddie Pashinski (D)
PA	SB 484	Referred to Senate Banking and Insurance Committee	Coupons/Cost Sharing	This measure limits how much a consumer will pay in cost-sharing for a specialty tier prescription drug to \$100 per month for a 30-day supply. Additionally, this measure caps aggregate cost-sharing of all specialty tier prescription drugs at \$200 per month.	Sen. Bob Mensch (R)
PA	SB 639	Referred to Senate Banking and Insurance Committee	Pharmacy Benefit Manager	This measure gives a pharmacy or pharmacist the right to provide a covered individual with information concerning the cost of a prescription drug, including the individual's cost share. This bill prohibits a pharmacy benefit manager (PBM) from prohibiting the disclosure of cost information by a pharmacy or pharmacist.	Sen. Kristin Phillips-Hill (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

PA	SB 731	Referred to Senate Banking and Insurance Committee	Coupons/Cost Sharing	Under this bill, an insurer must include any cost-sharing amounts paid by the insured or on behalf of the insurer by another person. A pharmacy benefits manager that administers pharmacy benefits for the insurer must include any cost-sharing amounts paid by the insured on or on health of the insured by another person.	Sen. Judith Ward (R)
PA	SB 789	Referred to Senate Health and Human Services Committee	Pharmacy Benefit Manager	This measure prohibits a medical assistance Medicaid managed care organization from entering into any contract for pharmacy services with a pharmacy benefits manager (PBM) if the PBM or corporate affiliate of the PBM has an ownership interest in a pharmacy providing the pharmacy services or if the pharmacy providing services has an ownership interest in the PBM or a corporate affiliate of the PBM. This bill also prohibits a PBM from requiring that an enrollee use the services of a specific pharmacy for a specialty drug.	Sen. David Argall (R)
PA	SB 825	Referred to Senate Health and Human Services Committee	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) that contracts with a medical assistance managed care organization (MCO) from using a confidentiality provision that prohibits the disclosure of information to the MCO or Department of Human Services upon request. This measure also requires PBMs under contract with MCOs to report differences between the amount paid by the MCO to the PBM and the amount paid by the PBM to pharmacies. Under this bill, the department will reimburse pharmacies in the fee-for-service delivery system as follows: the lower of the National Average Drug Acquisition Cost (NADAC) per unit with a dispensing fee or the usual and customary charge for the drug dispensed. If the NADAC is not available, reimbursement will be the lower of the wholesale acquisition cost with a dispensing fee or the usual and customary charge.	Sen. Judith Ward (R)
PA	SB 828	Referred to Senate Banking and Insurance Committee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at a default cap of \$100. The Insurance Commission must annually adjust the default cap based on the annual cost-of-living adjustment.	Sen. Daylin Leach (D)
PA	SB 829	Referred to Senate Health and Human Services Committee	Pharmacy Benefit Manager	This measure allows the Department of the Auditor General to conduct an audit and review of a pharmacy benefits manager (PBM) that contracts with a medical assistance managed care organization (MCO) under contract with the department. This measure also stipulates that a PBM owes a duty of care and loyalty and is obligated to act in good faith in relation to the department and any medical assistance MCO with which the PBM contracts.	Sen. Ryan Aument (R)
RI	H 5094	Referred to House Corporations Committee	Transparency	This measure requires the identification of 15 prescription drugs for which the state spends significant health care dollars due to an increase in costs and requires the drugs' manufacturers to provide relevant information to justify price increases. Drugs that have increased in price by 50% or more over the past five years, or by 15% or more in the last year, may be added to the list. This measure also instructs the Department of Health to study how other states' Medicaid programs use 340B pricing and the possible benefits of offering 340B pricing to consumers. Additionally, this bill requires the department to convene an advisory commission to develop options for all qualified health benefit plans to be offered for the 2021 plan year, including one or more plans with a higher out-of-pocket limit on prescription drug coverage than the limit established under current law and two or more plans with an out-of-pocket limit at or below the limit established under current law.	Rep. John Lombardi (D)
RI	H 7039	House Corporations Committee recommended bill be held for further study	Transparency	This measure requires the identification of 15 prescription drugs for which the state spends significant health care dollars due to an increase in costs and requires the drugs' manufacturers to provide relevant information to justify price increases. Drugs that have increased in price by 50% or more over the past five years, or by 15% or more in the last year, may be added to the list. This measure also instructs the Department of Health to study how other states' Medicaid programs use 340B pricing and the possible benefits of offering 340B pricing to consumers. Additionally, this bill requires the department to convene an advisory commission on out-of-pocket prescription drug costs.	Rep. John Lombardi (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

RI	H 7121	Referred to House Health, Education and Welfare Committee	Cost Review (Rate Setting)	<p>This measure establishes a Prescription Drug Affordability board. The board will study the entire pharmaceutical distribution and payment system in the state and any policy options being used in other states and countries to lower the list price of pharmaceuticals, including setting upper payment limits, using a reverse auction marketplace and implementing a bulk purchasing process.</p> <p>The board must also collect and review publicly available information regarding prescription drug product manufacturers, health insurance carriers, health maintenance organizations, managed care organizations and pharmacy benefit managers and identify states that require reporting on the cost of drugs.</p> <p>The board must identify brand-name drugs that have a launch wholesale acquisition cost of \$30,000 per year or a WAC increase of \$3,000 or more in a year; biosimilar drugs that have a launch WAC that is not at least 15% lower than the referenced brand biologic, and generic drugs that have a WAC of \$100 or more that increase by 200% or more during the past year. The board may conduct a cost review of any of the drugs identified to determine whether they create affordability challenges. If the board determines a drug under review creates an affordability challenge, it may set an upper payment limit for the drug.</p>	Rep. Joseph McNamara (D)
RI	H 7126	Referred to House Health, Education and Welfare Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured is required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed.	Rep. Brian Kennedy (D)
RI	S 136	Held in Senate Health and Human Services Committee	Other	This measure requires prescription drug manufacturers to file a detailed, updated list of each pharmaceutical sales representative.	Sen. Joshua Miller (D)
RI	S 137	Referred to Senate Health and Human Services Committee	Coupons/Cost Sharing	This measure requires a manufacturer who offers a discount or coupon to publish on any accompanying advertisement and website a message that a generic alternative may be available at a lower price. This bill also requires that if a manufacturer makes available to an insured consumer any discount, the manufacturer must make that same discount available to any person in the state, whether or not that person has health insurance.	Sen. Joshua Miller (D)
RI	S 2122	Referred to Senate Health and Human Services Committee	Transparency	This measure requires prescription drug manufacturers to file a detailed, updated list of each pharmaceutical sales representative who markets prescription drugs in the state. Each representative on the list will be required to submit an annual report that includes a list of providers to whom the representative provided any type of compensation that exceeds \$10 or total compensation with a value that exceeds \$100 in aggregate, as well as the name and manufacturer or each prescription drug for which the representative provided a free sample.	Sen. Joshua Miller (D)
RI	S 2318	Referred to Senate Health and Human Services Committee	Transparency	<p>This measure requires pharmaceutical drug manufacturers to provide wholesale acquisition cost (WAC) information to the Department of Health. Manufacturers will have to report drugs with a WAC of at least \$100 for a 30-day supply that has increased by 40% or more in three years or 15% or more in the preceding calendar year.</p> <p>This bill also requires pharmacy benefit managers (PBMs) to provide information relating to drug prices, rebates, fees, and drug sales to the Health Insurance Commissioner on a yearly basis. Under this measure, each health benefit plan issuer must submit to the Insurance Commissioner a report detailing the names of the 25 most frequently prescribed drugs, the percent increase in annual net spend for prescription drugs, and the percent increase in premiums that were attributable to prescription drugs.</p>	Sen. Dominick Ruggerio (D)
RI	S 2319	Referred to Senate Health and Human Services Committee	Other	This measure limit's beneficiaries' out-of-pocket expenditures for prescription drugs to limits established for self-only and family coverage per year established in the Internal Revenue Code.	Sen. Michael McCaffrey (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

RI	S 2320	Referred to Senate Health and Human Services Committee	Cost Review (Rate Setting)	<p>This measure establishes a Prescription Drug Affordability Board. The board will study the entire pharmaceutical distribution and payment system in the state and any policy options being used in other states and countries to lower the list price of pharmaceuticals, including setting upper payment limits, using a reverse auction marketplace and implementing a bulk purchasing process.</p> <p>The board must also collect and review publicly available information regarding prescription drug product manufacturers, health insurance carriers, health maintenance organizations, managed care organizations and pharmacy benefit managers and identify states that require reporting on the cost of drugs.</p> <p>The board must identify: 1) brand-name drugs that have a launch wholesale acquisition cost (WAC) of \$30,000 per year or a WAC increase of \$3,000 or more in a year; 2) biosimilar drugs that have a launch WAC that is not at least 15% lower than the referenced brand biologic; and (3) generic drugs that have a WAC of \$100 or more that increase by 200% or more during the past year. The board may conduct a cost review of any of the drugs identified to determine whether they create affordability challenges. If the board determines a drug under review creates an affordability challenge, it may set an upper payment limit for the drug.</p>	Sen. Cynthia Coyne (D)
RI	S 2321	Referred to Senate Health and Human Services Committee	Importation	This measure allows for the wholesale importation of prescription drugs from Canada.	Sen. Louis DiPalma (D)
RI	S 2322	Referred to Senate Health and Human Services Committee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at \$50.	Sen. Melissa Murray (D)
RI	S 2323	Referred to Senate Health and Human Services Committee	Pharmacy Benefit Manager	This measure requires pharmacist to advise on lower-cost generic alternatives and prevents pharmacy benefit managers from penalizing pharmacist who share such information.	Sen. Walter Felag (D)
SC	H 5113	Referred to House Labor, Commerce and Industry Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured is required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed.	Rep. Cezar McKnight (D)
TN	HB 884	Introduced	Pharmacy Benefit Manager	This measure prohibits pharmacy benefit managers from prohibiting a pharmacy or pharmacist from informing patients of all relative options pertaining to their prescription medications, including the cost or effectiveness of alternative medications, and whether a cash payment would cost less than any cost-sharing amounts.	Rep. Vincent Dixie (D)
TN	HB 887/SB 963	Referred to House Health Subcommittee on Mental Health and Substance Abuse/referred to Senate Commerce and Labor Committee	Transparency	This measure prohibits pharmacy benefit managers from prohibiting a pharmacy or pharmacist from informing patients of all relative options pertaining to their prescription medications, including the cost or effectiveness of alternative medications, and whether a cash payment would cost less than any cost-sharing amounts.	Rep. Vincent Dixie (D), Sen. Brenda Gilmore (D)
TN	HB 1179/ SB 987	Referred to House Insurance Subcommittee on Life and Health Insurance/Referred to Senate Commerce and	Pharmacy Benefit Manager	This measure authorizes the Bureau of TennCare to negotiate supplemental manufacturer rebates for TennCare prescription drug purchases. When conducting negotiations, the bureau must utilize the average manufacturer's price as the cost basis for the product.	Rep. Bryan Terry (R), Sen. Shane Reeves (R)
TN	HB 1890/SB 1942	Referred to House Life and Health Insurance Subcommittee/ Introduced	Pharmacy Benefit Manager	This measure prohibits a pharmacy benefit manager (PBM) from discriminating against a 340B entity: (1) in a manner that prevents or interferes with the patient's choice to receive those drugs from the 340B entity; or (2) regarding reimbursement for pharmacy-dispensed drugs by reimbursing at a rate lower than that paid for the same drug to pharmacies that are not 340B entities.	Rep. Esther Helton (R), Sen. Richard Briggs (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

TN	HB 1931/SB 1939	Referred to House Life and Health Insurance Subcommittee/Referred to Senate Commerce and Labor Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured is required to pay for a prescription drug at \$100 per 30-day supply.	Rep. Jason Hodges (D), Sen. Richard Briggs (R)
TN	HB 1959/SB 2419	Referred to House Life and Health Insurance Subcommittee/Referred to Senate Commerce and Labor Committee	Pharmacy Benefit Manager	This measure prohibits gag clauses in pharmacy benefit manager (PBM) contracts with pharmacies and pharmacists.	Rep. Vincent Dixie (D), Sen. Katrina Robinson (D)
TN	HB 2379/SB 2374	Introduced/Referred to Senate Commerce and Labor Committee	Study	This measure urges the Board of Pharmacy to conduct a study of the effects of prescription drug advertising in pharmacies in Tennessee, with a focus on advertising targeted at the consumer.	Rep. Susan Lynn (R), Sen. Shane Reeves (R)
TN	HB 2575/SB 2786	Referred to House Life and Health Insurance Subcommittee/ Introduced	Pharmacy Benefit Manager	This measure decreases from five to three business days the date by which a pharmacy benefit manager (PBM) must remove a drug from the maximum allowable cost list following the date that the PBM becomes aware that the drug no longer is generally available for purchase by pharmacies in the state.	Rep. Robin Smith (R), Sen. Ed Jackson (R)
TN	HB 2688/SB 2377	Referred to House Life and Health Insurance Subcommittee/Referred to Senate Commerce and Labor Committee	Other	This measure requires health plans, pharmacy benefit managers, and pharmacies to make available a patient's specific prescription cost and benefit information available in real-time for usage in a health care provider's prescribing or electronic health record system at the point of prescribing and dispensing.	Rep. Timothy Hill (R), Sen. Shane Reeves (R)
TN	SB 1718/HB 1832	Referred to Senate Commerce and Labor Committee/Referred to House Life and Health Insurance Subcommittee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can require a covered patient with diabetes to pay for a 30-day supply of insulin at \$100. This measure also requires the Department of Health and the Division of Consumer Affairs to study and investigate the pricing of prescription insulin drugs and report findings to the legislature.	Sen. Katrina Robinson (D), Rep. Vincent Dixie (D)
UT	HB 207	Referred to House Health and Human Services Committee	Coupons/Cost Sharing	This measure requires health benefit plans to cap the total amount that an insured is required to pay for insulin at an amount not to exceed \$30 per 30-day supply, regardless of the amount of type of insulin needed. The cap must be applied regardless of whether the insured has met the plan's deductible. This cap does not apply to health plans that cover insulin under the lowest tier of drugs and do not require an insured to meet a deductible before the plan will cover insulin at the lowest tier. This measure also directs the Public Employees' Benefit and Insurance Program to purchase insulin at discount prices and to create a program that allows public employees to access that discounted insulin at the fully discounted, post-rebate price.	Sen. Norm Thurston (R)
UT	HB 239	Introduced	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured individual is required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed.	Rep. Marie Poulson (D)
UT	HB 249	Introduced	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured individual is required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed.	Rep. Melissa Ballard (R)
UT	HB 263	Introduced	Transparency	This measure requires prescription drug manufacturers to provide notice of certain drug cost information. Under this bill, a manufacture must provide notice at least 60 days prior to an increase in the wholesale acquisition cost (WAC) of a qualified drug of 10% or more over the preceding year. This bill defines a "qualified drug" as a drug whose WAC increases by 10% over a 12-month period. The notice must also contain cost information. Additionally, if a new drug has a WAC that exceeds the upper limit payment for specialty drugs under Medicare, the manufacture of that drug must submit the WAC of the new drug, along with a description of the marketing and pricing plans used in the launch of the drug.	Rep. Mike Winder (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

UT	HB 272	Referred to House Health and Human Services Committee	Pharmacy Benefit Manager	This measure requires the Insurance Department to annually publish the total value of rebates and administrative fees received by a pharmacy benefit manager (PBM) from a manufacturer. This bill prohibits a PBM from reducing a pharmacy's total compensation for the sale of a drug, device, or other product unless the PBM provides the pharmacy with at least 30-days notice, as well as from retroactively denying or reducing a claim. This bill requires a health benefit plan's terms and conditions for pharmacy coverage to be applied uniformly across enrollees and pharmacies and prohibits an insurer from promoting the use of one pharmacy in a network over another, as well as from requiring the use of an out-of-state mail services pharmacy as a condition for pharmacy coverage. This bill additionally requires PBMs to distribute unretained manufacturer rebates to insurers and enrollees. This bill requires pharmaceutical manufacturers to report to the legislature at least once each calendar quarter the wholesale acquisition cost of each of the manufacturer's prescription drugs that are available for purchase by residents of the state.	Rep. Paul Ray (R)
VA	HJ 52	House voted to block passage	Study	This measure urges the House of Delegates, the Senate, and the Secretary of Health and Human Resources to study the pharmaceutical distribution payment system in the state and innovative solutions to address the cost of prescription drugs to Virginians at the point of sale. The review must include a review of transparency for pharmaceutical manufacturers, pharmacy benefit managers, and health insurance carriers. The Secretary of Health and Human Resources will be required to submit a summary of the group's findings and any legislative recommendations to the legislature by Nov. 1, 2020.	Del. Elizabeth Guzman (D)
VA	HB 29	Referred to House Appropriations Committee	Pharmacy Benefit Manager	These provisions are included in one of the state budget bills. This bill requires the Department of Human Resource Management to include language in all contracts with third-party administrators (TPAs) to maintain policies and procedures for transparency in pharmacy benefit administration programs. This measure also requires all TPAs to provide a report to the department that details the aggregate difference in amounts between reimbursements made to pharmacies for claims covered by the state employee insurance plan, the amount charged to the TPA by the TPA's pharmacy benefit manager and the amount charged by the TPA to the state, as well as any explanation for any difference. This measure also requires the Department of Medical Assistance Services to amend the State Plan for Medical Assistance Services to modify the delivery system of pharmaceutical products to include a preferred drug list.	Del. Luke Torian (D)
VA	HB 30	Referred to House Appropriations Committee	Pharmacy Benefit Manager	These provisions are included in one of the state budget bills. This bill requires the Department of Human Resource Management to include language in all contracts with third-party administrators (TPAs) to maintain policies and procedures for transparency in pharmacy benefit administration programs. This measure also requires all TPAs to provide a report to the department that details the aggregate difference in amounts between reimbursements made to pharmacies for claims covered by the state employee insurance plan, the amount charged to the TPA by the TPA's pharmacy benefit manager and the amount charged by the TPA to the state, as well as any explanation for any difference. This measure also requires the Department of Medical Assistance Services to amend the State Plan for Medical Assistance Services to modify the delivery system of pharmaceutical products to include a preferred drug list.	
VA	HB 66	Passed House; referred to Senate Commerce and Labor Committee	Coupons/Cost Sharing	This measure caps cost-sharing payments for prescription insulin drugs at \$30 for 30-day supply of insulin.	Del. Lee Carter (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

VA	HB 691	Carried over to 2021	Cost Review (Rate Setting)	<p>This measure establishes the Prescription Drug Affordability Board, which must study, review, and regulate the cost of prescription drugs. The board will be made up of seven non-legislative members appointed by the governor and confirmed by the General Assembly. The board will have the power to collect, review, and study publicly available information regarding drug manufacturers, health insurance carriers, health maintenance organizations, managed care organizations, wholesale distributors and pharmacy benefit managers. The board must identify states that require reporting on the cost of drug and initiate a process to enter into a memoranda of understanding with those states to aid in the collection of transparency data for prescription drugs.</p> <p>The board must review brand-name drugs that enter the market at \$30,000 per year or existing brand drugs that increase in price by \$3,000 or more per year. The board must review generic medications that increase by 200% or more per year as well as any drugs that could create affordability challenges to the state.</p> <p>Under this bill, the board must study policy options used in other states to lower the list price of pharmaceuticals, including setting upper payment limits, using a reverse auction marketplace, and implementing a bulk purchasing process. This measure requires the board to consider a board range of economic factors when recommending and setting appropriate payment rates for reviewed drugs, including a review of the entire supply chain and allowing pharmaceutical manufacturers the opportunity to justify existing drug costs. A report is due to the General Assembly on ways to mitigate high drug costs by Jan. 1, 2023.</p>	Rep. Shelly Simonds (D)
VA	HB 876	Carried over to 2021	Transparency	<p>This measure requires health carriers to report spending on prescription drugs in total and for each of the 25 most frequently prescribed drugs, including the greatest total spending, the greatest total spending per user of any drug in the drug group, the highest year-over-year increase in total spending and the highest year-over-year increase in total spending per user of any drug in the drug group. Each carrier must also report projected total spending before enrollee cost sharing for the current year and any price concessions and fees paid to pharmacy benefit managers (PBMs) and other retail price concessions.</p> <p>Additionally, each health plan must require each PBM with which it contracts to report: the wholesale acquisition cost (WAC) for each drug and drug group for which the PBM has negotiated directly with the manufacturer; the volume in WAC units the PBM negotiated directly with manufacturers; the projected volume in WAC units the PBM negotiated directly with the manufacturer; total rebates and prices concessions negotiated with manufacturers, pharmacies and pharmacy services administrative organizations; and total net income.</p> <p>Drug manufacturers will have to report similar information, along with 60 days' advance notice of any introduction to the market of any new brand or generic drugs with a WAC of more than \$670 per year. Manufacturers will have to provide 60 days' advance notice if a brand drug's WAC increases by 20% or if a generic drug that costs at least \$100 increases by 200%.</p> <p>This measure requires the Department of Health to annually collect, compel and make available on its website information about prescription drug prices submitted by health carriers, pharmacy benefit manufacturers and wholesale distributors.</p>	Del. Suhas Subramanyam (D)
VA	HB 1290	Introduced	Pharmacy Benefit Manager	<p>This measure requires pharmacy benefit managers (PBMs) to obtain a license from the State Corporation Commission before operating in the state. This measure also requires insurance carriers to allow the commissioner to examine or audit the records of a PBM, and makes carriers responsible for charges incurred during any audit. The bill also requires PBMs to submit quarterly reports detailing rebate information.</p>	Del. Keith Hodges (D)
VA	HB 1291	House voted to block passage	Pharmacy Benefit Manager	<p>This measure prohibits pharmacy benefit managers (PBMs) that contract with Medicaid managed care organizations from conducting spread pricing.</p>	Del. Keith Hodges (D)
VA	HB 1292	House Labor and Commerce Committee Incorporated into HB 1290	Pharmacy Benefit Manager	<p>This measure prohibits health insurance carriers from entering into or renewing contracts with pharmacy benefit managers (PBMs) unless those contract prohibit the use of spread pricing by the PBM.</p>	Del. Keith Hodges (D)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

VA	HB 1403	House Labor and Commerce Committee Subcommittee #2 recommends incorporating into HB 66	Coupons/Cost Sharing	This measure prohibits health insurance companies from charging an enrollee more than \$100 per 30-day supply of insulin.	Del. James Leftwich (R)
VA	HB 1404	House Health, Welfare and Institutions Committee Subcommittee on Health recommends striking from docket	Importation	This measure requires the Department of Health to propose a wholesale prescription drug importation program that complies with federal requirements by July 1, 2021.	Del. James Leftwich (R)
VA	HB 1405	Referred to House Health, Welfare and Institutions Committee	Transparency	This measure requires drug pricing transparency for diabetes medication. Under this bill, every manufacturer that sells diabetes medication in the state must report cost information, including the cost of manufacturing, and distributing the drug, the wholesale acquisition cost (WAC), and the cost of marketing. If an insulin product's WAC increases by a percentage greater than the consumer price index, the manufacturer of that product will be required to submit additional pricing information. Pharmacy benefit managers (PBMs) will have to report similar information for diabetes products. The Health Commissioner must then conduct an analysis of the information submitted by manufacturers and PBMs, which will be published on the department's website. This measure also requires PBMs to register with the Insurance Department.	Del. James Leftwich (R)
VA	HB 1459	House Labor and Commerce Committee incorporated into HB 1290	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to register with the Insurance Commissioner before operating in the state. This measure prohibits PBMs from charging enrollees a cost-sharing amount above a certain threshold and from engaging in patient steering. This bill also dictates how often a PBM must update its maximum allowable cost (MAC) list and the process by which a pharmacy can appeal the provider's reimbursement for a drug subject to MAC pricing.	Del. Israel O'Quinn (R)
VA	HB 1479	House Labor and Commerce Committee incorporated into HB 1290	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to register with the Insurance Commissioner before operating in the state. This measure prohibits PBMs from charging enrollees a cost-sharing amount above a certain threshold and from engaging in patient steering. This bill also dictates how often a PBM must update its maximum allowable cost (MAC) list and the process by which a pharmacy can appeal the provider's reimbursement for a drug subject to MAC pricing.	Del. Ibraheem Samirah (D)
VA	HB 1659	House Labor and Commerce Committee incorporated into HB 1290	Pharmacy Benefit Manager	This measure prohibits a health insurance carrier from entering into a contract with a pharmacy benefit manager (PBM) unless the contract contains provisions prohibiting the PBM from reimbursing a pharmacy in an amount less than the amount that the pharmacy benefit manager reimburses an affiliate for providing the same services.	Del. Christopher Head (R)
VA	SB 251	Passed Senate	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to obtain a license before operating in the state. The bill also requires PBMs to submit quarterly reports detailing rebate information. This measure prohibits a PBM from using false advertisement and from including any mail order pharmacy or PBM affiliate when calculating or determining network adequacy.	Sen. John Edwards (D)
VA	SB 252	Incorporated into SB 251 by Senate Commerce and Labor Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to obtain a license from the State Corporation Commission before operating in the state. This measure also prohibits PBMs from engaging in spread pricing and provides that except for any agreed-upon administrative fee, all funds, including any rebates received by the PBM, will be distributed to the carrier.	Sen. John Edwards (D)
VA	SB 424	Referred to Senate Commerce and Labor Committee	Coupons/Cost Sharing	This measure requires insurance carriers to include any amounts paid on behalf of an enrollee for a prescription drug toward the enrollee's overall contribution to any out-of-pocket maximums, including the amount of any rebates received by the carrier or its pharmacy benefit manager in connection with the dispensing or administration of a prescription drug.	Sen. Bill DeStaph (R)
VA	SB 568	Passed Senate	Pharmacy Benefit Manager	This measure requires the Board of Medical Assistance to select, every four years, a third-party administrator to serve as the state pharmacy benefit manager (PBM) used by Medicaid managed care organizations (MCOs). Under the bill, the state PBM is responsible for all pharmacy claims under the state plan. In selecting the state PBM, the board must establish eligibility criteria, develop a master contract to be used by each Medicaid MCO when contracting with the state PBM, and establish mandatory disclosures for a prospective state PBM. The state PBM will be required to develop a drug formulary for use when administering prescribed drugs on behalf of a Medicaid MCO.	Sen. Siobhan Dunnavant (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

VA	SB 573	Referred to the Senate Commerce and Labor Committee	Coupons/Cost Sharing	This measure requires insurance carriers to include any amounts paid on behalf of an enrollee for a prescription drug toward the enrollee's overall contribution to any out-of-pocket maximums, including the amount of any rebates received by the carrier or its pharmacy benefit manager in connection with the dispensing or administration of a prescription drug.	Sen. Siobhan Dunnivant (R)
VA	SB 862	Incorporated into SB 251 by Senate Commerce and Labor Committee	Pharmacy Benefit Manager	This measure requires pharmacy benefit managers (PBMs) to register with the Insurance Commissioner before operating in the state. This measure prohibits PBMs from charging enrollees a cost-sharing amount above a certain threshold and from engaging in patient steering. This bill also dictates how often a PBM must update its maximum allowable cost (MAC) list and the process by which a pharmacy can appeal the provider's reimbursement for a drug subject to MAC pricing.	Sen. Todd Pillion (R)
VT	H 785	Referred to House Health Care Committee	Cost Review (Rate Setting)	This measure proposes to authorize and direct the Green Mountain Care Board to evaluate the costs of certain high-cost drugs and recommend methods for addressing those costs. Under this bill, the board must identify: i) brand-name drugs or biologics that has a launch wholesale acquisition cost (WAC) of \$30,000 per year or a WAC increase of \$3,000 or more in a year; ii) biosimilar drugs that have a launch WAC that is not at least 15 percent lower than the brand reference at the time of launch; and iii) generic drugs that have a WAC of \$100 or more and that increased by 200 percent or more in a year. This measure also lays out the criteria by which the board will determine whether a drug that meets the above thresholds creates an affordability challenges. If the board finds that spending on a drug reviewed has led or may lead to affordability challenges, the board will establish an upper payment limit for the drug which will apply to all purchases of an payer reimbursements for the drug dispensed or administered in the state. The Prescription Drug Affordability Stakeholder Group will help the board make determinations.	Rep. Sarah Copeland Hanzas (D)
VT	H 822	Referred to House Health Care Committee	Coupons/Cost Sharing	This measure requires a health insurer to limit a beneficiary's out-of-pocket expenditure for prescription insulin drugs to not more than \$100 per 30-day supply. This measure also directs the Attorney General to investigate the pricing of insulin and report to the General Assembly whether adequate consumer protections exist for the pricing of those drugs.	Rep. Mari Cordes (D)
VT	S 136	Referred to Senate Health and Welfare Committee	Importation	This measure designates the Agency of Human Services as the state entity responsible for developing and implementing a wholesale Canadian drug importation program. This measure also authorizes the Vermont Board of Pharmacy to create two new prescription drug wholesaler licenses for certain market participants in the program.	Sen. Christopher Pearson (D)
VT	S 296	Referred to Senate Finance Committee	Coupons/Cost Sharing	This measure requires a health insurer to limit a beneficiary's out-of-pocket expenditure for prescription insulin drugs to not more than \$100 per 30-day supply, regardless of the amount or type of insulin needed to fill the prescription.	Sen. Cheryl Hooker (D)
WA	HB 1562/SB 5601	Referred to House Health Care and Wellness Committee/Substituted; passed Senate Ways and Means Committee; referred to Senate Rules Committee	Pharmacy Benefit Managers	This measure requires health benefit managers to obtain a license and prohibits a health benefit manager from reimbursing a pharmacy or pharmacist in the state an amount less than the amount the pharmacy benefit manager reimburses an affiliate for providing the same services. This measure also prohibits PBMs from retroactively denying or reducing claims.	Rep. Monica Stonier (D), Sen. Christine Rolfes (D)
WA	HB 1911	Referred to House Health Care and Wellness Committee	Pharmacy Benefit Manager	This measure requires licensure for pharmacy benefit managers.	Rep. Joe Schmick (R)
WA	HB 2662	Substituted; passed House Appropriations Committee; referred to House Rules Committee	Coupons/Cost Sharing	This measure creates the Total Cost of Insulin work group, which must submit a report to the governor and legislature detailing strategies to reduce the cost of and total expenditures on insulin for patients, carriers and the state. This measure also requires health plans to cap cost-sharing for insulin at \$100 per 30-day supply.	Rep. Jacquelin Maycumber (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

WA	SB 5251	Introduced; referred to Senate Health and Long Term Care Committee	Transparency	<p>This measure requires insurers to submit an annual report to the Office of Financial Management with drug cost information for the top 25 most frequently prescribed drugs, the top 25 costliest drugs, and top 25 drugs with the highest year-over-year increase in spending. Insurers must also report the per member, per month year-over-year increase in the total annual cost of each category listed, as well as the 25 most frequently prescribed drugs for which the issuer received rebates from manufacturers. This measure also requires pharmacy benefit managers to submit information on rebates. The office will compile the information into a report for the public and the legislature.</p> <p>This measure requires prescription drug manufacturers to provide notice to the Health Care Authority when the manufacturer has filed a new drug application or biologics license application for a pipeline drug or biosimilar drug. Notice must be provided within 60 days of the manufacturer receiving an action date from the US Food and Drug Administration.</p> <p>This measure requires the Health Care Authority to create an annual drug list of the 10 prescription drugs that have a large impact on state spending or a critical to public health. Drugs will only be included if they have increased by at least 20% in a year or 50% in three years and if they cost at least \$100 for a 30-day supply. Manufacturers of drugs on this list must provide information regarding the prices of the drugs.</p>	Sen. Mark Mullet (D)
WA	SB 5422	Referred to Senate Health and Long Term Committee	Pharmacy Benefit Managers	<p>This measure establishes that pharmacy benefit managers (PBMs) have a fiduciary duty to a health carrier client. This measure also prohibits a PBM from requiring an enrollee to make a payment at the point of sale for a covered prescription medication in an amount greater than the lesser of the applicable copayment or the allowable claim amount, the amount an enrollee would pay without insurance, or the amount the PBM or carrier will reimburse the pharmacy for the drug. This measure also requires PBMs to submit annually a transparency report regarding aggregate rebates.</p>	Sen. Patty Kuderer (D)
WA	SB 5982	Referred to Senate Health and Long Term Care Committee	Pharmacy Benefit Manager	<p>This measure requires the licensure, rather than registration, of pharmacy benefit managers (PBMs). This measure also establishes that a PBM has a fiduciary duty to a health carrier client. This bill prohibits a PBM from reimbursing a pharmacy an amount less than the amount the PBM reimburses a PBM affiliate for providing the same services. Under this bill, a PBM may not deny, reduce, or recoup payment to a pharmacy after adjudication of a claim.</p>	Sen. Shelly Short (R)
WA	SB 6087	Referred to Senate Rules Committee	Coupons/Cost Sharing	<p>This measure places a cap on the total amount than an insured individual is required to pay for a prescription drug at \$100 per 30-day supply. This measure allows health plans to raise the cost-sharing amount for a 30-day supply by \$5 for every \$100 increase in the cost of an insulin product to the health plan.</p>	Sen. Karen Kiser (D)
WA	SB 6088	Substituted; passed Senate Ways and Means Committee; referred to Senate Rules Committee	Cost Review (Rate Setting)	<p>This measure establishes a prescription drug affordability board that will be responsible for identifying high-cost drugs, superficially: (i) brand name drugs that are introduced with a wholesale acquisition cost (WAC) of \$30,000 or more per year or have a price increase of \$3,000 or more in a year; (ii) biosimilars with a WAC of less than 15% below the reference brand biologic product; (iii) generics with a WAC of \$100 or less that has increase by 200% or more in the preceding 12 months; and (iv) any other drugs that may create excess costs or the state and patients. For drugs chose for cost review, the board must determine whether the drug has led or will lead to excess costs to the state or patients. If a drug is deemed to have an excessive cost, the board can set an upper payment limit for the drug.</p>	Sen. Karen Keiser (D)
WA	SB 6110	Referred to Senate Health and Long Term Care Committee	Importation	<p>This measure requires the Health Care Authority to design a wholesale prescription drug importation program that complies with federal requirements by July 1, 2021.</p>	Sen. Karen Keiser (D)
WA	SB 6113	Substituted; passed Senate Ways and Means Committee; referred to Senate Rules Committee	Other	<p>This measure establishes the central insulin purchasing work group that must submit a report to the governor and legislature by December 1, 2020, detailing the purchasing plan and any statutory changes necessary to implement the plan. The work group must design a purchasing strategy to allow the Northwest Prescription Drug Consortium to act as the single purchaser of insulin for the state.</p>	Sen. Karen Kiser (D)
WV	HB 2319	Referred to House Health and Human Resource Committee	Importation	<p>This measure requires the Bureau for Medical Services to establish a state-administered wholesale importation program where the state is the licensed wholesaler, importing drugs from licensed, regulated Canadian suppliers.</p>	Del. Mick Bates (D)
WV	HB 2428	Referred to House Health and Human Resource Committee	Importation	<p>This measure requires the Bureau for Medical Services to establish a state-administered wholesale importation program where the state is the licensed wholesaler, importing drugs from licensed, regulated Canadian suppliers.</p>	Del. Joe Ellington (R)
WV	HB 4062	Referred to House Health and Human Resources Committee	Pharmacy Benefit Manager	<p>This measure requires all compensation remitted by or on behalf of a pharmaceutical manufacturer to a carrier or pharmacy benefits manager (PBM) to be either remitted directly to the covered person at the point of sale to reduce out-of-pocket costs or retained by the carrier for the purpose of lowering premiums.</p>	Del. Jeffrey Pack (R)

National Academy for State Health Policy
State Prescription Drug Legislative Tracker 2020

WV	HB 4087/SB 577	Referred to House Banking and Insurance Committee/Referred to Senate Banking and Insurance Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured individual s required to pay for a prescription drug at \$25 per 30-day supply, regardless of the amount or type of insulin needed.	Del. Barbara Fleischauer (D), Sen. Roman Prezioso (D)
WV	HB 4543	Passed House Banking and Insurance Committee; referred to House Judiciary Committee	Coupons/Cost Sharing	This measure caps the total amount that a carrier can required a covered patient with diabetes to pay for a 30-day supply of insulin at \$25, regardless of the quantity or type of insulin needed to fill the person's needs. This measure prohibits a manufacturer, wholesaler, or pharmacy benefit manager from passing through the costs of the drug to the pharmacist or pharmacy.	Del. Jordan Hill (R)
WV	HB 4554	Referred to House Banking and Insurance Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured individual s required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed.	Del. Cindy Lavendar-Bowe (D)
WV	HB 4583/SB 689	Amended; passed House Health and Human Resources Committee; referred to House Government Organization Committee/Referred to Senate Health and Resources Committee	Transparency	<p>This measure requires drug manufacturers to submit an annual report to the auditor. This applies to generic, brand and specialty drugs with a wholesale acquisition cost (WAC) off at least \$100 and a WAC increase of 40% or more over the preceding three years or 15% of more in the previous year. The report must include pricing information.</p> <p>This measure also requires each health benefit plan to submit a report to the state auditor regarding the names of the 25 most frequently prescribed drugs, the percent increase in annual net spending for prescription drugs, the percent increase in premiums that were attributable to prescription drugs, the percentage of specialty drugs with utilization management requirements, and the premium reductions that were attributable to specialty drug utilization management.</p> <p>This bill also requires the auditor to create a searchable pharmaceutical price transparency website.</p>	Del. Joseph Jeffries (R), Sen. Mike Maroney (R)
WV	HB 4789	Referred to House Banking and Insurance Committee	Importation	This measure allows the Department of Health and Human Services to seek federal authority for a wholesale drug importation program.	Del. Evan Worrell (R)
WV	SB 43	Referred to Senate Banking and Insurance Committee	Coupons/Cost Sharing	This measure places a cap on the total amount than an insured individual is required to pay for a prescription drug at \$100 per 30-day supply, regardless of the amount or type of insulin needed.	Sen. Sue Cline (R)
WV	SB 89	Referred to Senate Health and Human Resources Committee	Importation	This measure requires the Department of Health and Human Resources to design a wholesale prescription drug importation program that complies with federal requirements.	Sen. Stephen Baldwin (D)
WV	SB 284	Referred to Senate Banking and Insurance Committee	Coupons/Cost Sharing	This measure requires insurers to include any cost sharing amounts paid by the insurer or on behalf of an enrollee by another person when calculating an insured's contribution to any applicable cost-sharing requirement, including the annual limitation on cost sharing.	Sen. Mitch Carmichael (R)
WV	SB 567	Referred to Senate Health and Human Resources Committee	Importation	This measure requires the Department of Health and Human Resources to design a wholesale prescription drug importation program that complies with federal requirements.	Sen. Roman Prezioso (D)
WV	SB 582	Referred to Senate Health and Human Resources Committee	Pharmacy Benefit Manager	This measure prohibits pharmacy benefit managers (PBMs) under contract with a Medicaid managed care organization from engaging in spread pricing, retroactively denying a claim, reducing payment to a pharmacy to an effective rate of reimbursement, including generic effective rates, or from reimbursing a pharmacy at an amount less than the national average drug acquisition cost. This measure also requires PBMs to report rebate information.	Sen. Roman Prezioso (D)
WV	SB 701/HB 4739	Referred to Senate Health and Human Resources Committee/Referred to House Banking and Insurance Committee	Pharmacy Benefit Manager	This measure requires pharmacy services administrative organizations to obtain a license from the Insurance Commissioner.	Sen. Tom Takubo (R), Del. Steve Westfall (R)

